

2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Priority:

[0001] This application claims the benefit of U.S. Provisional Application No. 61/792,812, filed March 15, 2013. The entire disclosure of this application is relied on and incorporated into this application by reference.

Description of the Text File Submitted Electronically:

[0002] The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: DECP_062_01US_SeqList_ST25.txt, date recorded: March 15, 2014, file size 18 kilobytes).

Field of the Invention

[0003] Disclosed are compounds which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

Background

[0004] Autoimmune diseases, including autoimmune arthritis, represent significant human diseases of high morbidity and prevalence. Rheumatoid arthritis affects ~ 0.6% of the world population (Firestein, G.S., Nature (2003) 423: 356). While the adaptive immune response, involving generation of auto-antibodies which react with tissue antigen, is involved in the etiology and initial propagation of these diseases (Edwards, J.C. et al, New England Journal of Medicine (2004) 350: 2572; Genovese, M.C. et al, New England Journal of Medicine (2005) 353: 1114), the chronic manifestations of tissue and joint damage are mediated in large part by cellular events mediated by the innate immune response (Firestein, G.S., Nature (2003) 423: 356; Paniagua, R.T. et al, Arthritis Research & Therapy (2010) 12: R32). Contributing cell types from the innate immune response which mediate chronic tissue damage include fibroblast-like synoviocytes, macrophages, mast cells, and osteoclasts.

[0005] Kinases represent a protein family that play critical roles in mammalian cell function, including cell proliferation, survival, motility, response to growth factors, and secretion of cytokines and other proinflammatory, proangiogenic, and immunomodulatory

substances. Thus, elucidation of kinases which mediate these events in fibroblast-like synoviocytes, macrophages, mast cells, and osteoclasts represents a rational approach to new therapies for the treatment of autoimmune diseases.

[0006] Imatinib is a marketed kinase inhibitor for the treatment of the cancer chronic myelogenous leukemia (CML, Druker, B.J. et al, New England Journal of Medicine (2001) 344: 1031) and for the treatment of gastrointestinal stromal tumors (GIST, Demetri, G.D., et al, New England Journal of Medicine (2002) 347: 472). Imatinib has also shown benefit in cancer patients co-presenting with autoimmune diseases such as rheumatoid arthritis (Ihara, M.K. et al, Clinical Rheumatology (2003) 22: 362; Eklund, K.K. and Joensuu, H., Ann Medicine (2003) 35: 362; Ames, P.R. et al, Journal of Rheumatology (2008) 35: 1682). The kinases inhibited by imatinib which confer its efficacy in the treatment of CML and GIST are BCR-ABL kinase and c-KIT kinase, respectively. Beyond these two kinases, other kinases inhibited by imatinib include c-FMS, PDGFR-*alpha*, and PDGFR-*beta* (Dewer, A.L. et al, Blood (2005) 105: 3127; Fabian, M.A. et al, Nature Biotechnology (2005) 23: 329).

[0007] Recent research disclosures have identified c-FMS kinase to be associated with activation of synovial macrophages, PDGFR kinase to be associated with activation of fibroblast-like synoviocytes, and c-KIT kinase to be associated with activation of mast cells (Paniagua, R.T., et al Journal of Clinical Investigation (2006) 116: 2633). c-FMS kinase has also been associated with the proliferation and differentiation of monocytes into macrophages and osteoclasts, which are recruited to mediate joint damage in rheumatoid arthritis (Paniagua, R.T. et al, Arthritis Research & Therapy (2010) 12: R32; Yao, Z. et al, Journal of Biological Chemistry (2006) 281: 11846; Patel, S. and Player, M.R. Current Topics in Medicinal Chemistry (2009) 9: 599; Pixley, F.J. et al, Trends in Cell Biology (2004) 14: 628).

[0008] In recent years, the importance of the tumor microenvironment in cancer motility, invasion, and metastasis has become more clearly defined. Specifically, the role of tumor-associated macrophages (TAMs) in tumor progression has been studied. These host (stromal) macrophages are recruited to tumor sites or to pre-metastatic niches to modify the tumor environment and render that environment more conducive to tumor motility, invasion and metastasis. These TAMs are known to express c-FMS receptor tyrosine kinase (also known as CSF-1R) on their surfaces and to rely on signaling through this kinase by binding to the activating ligands CSF-1 (also known as macrophage colony stimulating factor, or MCSF) and interleukin-34 (IL-34). Activation of this c-FMS/MCSF (CSF1-R/CSF-1) signaling axis stimulates monocyte proliferation, differentiation into tumor associated macrophages, and

promotion of macrophage cell survival. By stimulating the TAM component of the tumor microenvironment, c-FMS kinase activation is associated with tumor cell migration, invasion, and metastasis (J. Condeelis and J.W. Pollard, *Cell* (2006) 124: 263; S. Patel and M.R. Player, *Current Topics in Medicinal Chemistry* (2009) 9: 599). Ablation of CSF-1, the ligand for c-FMS kinase, in mice reduced tumor progression and significantly reduced metastasis in a murine model of breast cancer; whereas overexpression of CSF-1 accelerated metastasis in this model (E.Y. Lin et al, *Journal of Experimental Medicine* (2001) 193: 727). Furthermore, an interaction between tumor cells and macrophages has been described, wherein macrophage secretion of the tumor growth factor EGF and tumor cell secretion of CSF-1 establish a paracrine loop that promotes tumor migration and invasiveness. This paracrine loop was blocked by administration of an antibody to the c-FMS kinase (J. Wyckoff et al, *Cancer Research* (2004) 64: 7022). Correlative clinical data have also shown that overexpression of CSF-1 in tumors is a predictor of poor prognosis (R.D. Leek and A.L. Harris, *Journal of Mammary Gland Biology Neoplasia* (2002) 7: 177; E.Y. Lin et al, *Journal of Mammary Gland Biology Neoplasia* (2002) 7: 147). c-FMS kinase activation is also required for osteoclast differentiation and activation. Its involvement in mediating bone metastases of various cancers, including breast and prostate cancers, has been reported (S. Patel and M.R. Player, *Current Topics in Medicinal Chemistry* (2009) 9: 599). High plasma concentrations of CSF-1 have been reported in bone metastatic prostate cancer, implicating activation of osteoclast c-FMS kinase in prostate cancer bone metastases (H. Ide, et al, *Human Cell* (2008) 21: 1). c-FMS inhibitors have been reported to reduce radiographic bone lesions when evaluated in models of metastatic bone disease (C.L. Manthey, et al, *Molecular Cancer Therapy* (2009) 8: 3151; H. Ohno et al, *Mol. Cancer Therapy* (2006) 5: 2634). MCSF-mediated activation of both LYVE-1+ and LYVE1- macrophages also mediates pathological angiogenesis and lymphangiogenesis in murine models of cancer, and blockade of c-FMS signaling resulted in suppression of tumor angiogenesis/lymphangiogenesis (Y. Kubota et al., *Journal of Experimental Medicine* (2009) 206: 1089). Administration of a CSF-1R inhibitor blocked the recruitment of bone marrow derived TAMs and also bone marrow derived monocytic myeloid-derived suppressor cells (MDSCs) to tumor sites; this blockade led to a significant decrease in tumor angiogenesis and when combined with anti-VEGFR-2 therapy synergistically suppressed tumor growth (S.J. Priceman, et al. *Blood* (2010) 115: 1461). Irradiation of glioblastoma tumors in mice was shown to cause a temporary decrease in tumor size only to be followed by a rebound tumor vasculogenesis


mediated by the recruitment of bone marrow derived monocytes expressing CD11b and F4/80 surface antigens (M. Kioi et al, Journal of Clinical Investigation (2010) 120: 694). CD11b+ and F4/80+ monocytes are also known to express functional c-FMS receptors. Hence, blockade of tumor infiltrating c-FMS+ bone marrow derived monocytes by the use of c-FMS kinase inhibitors offers the potential to prevent tumor rebound vasculogenesis and glioblastoma tumor progression. CSF-1R blockade has also been shown to reverse immunotolerance mechanisms in an immunocompetent murine breast cancer model and promote the appearance of anti-tumor immune programs by upregulating CD8+ T-cell-mediated tumor suppression. Restoration of an anti-tumor immune program was mechanistically linked to c-FMS inhibitor blockade of TAM-mediated Programmed Death Ligand-1 (PDL-1) immunotolerance (D. G. DeNardo, et al. Cancer Discovery (2011) 1: OF52).

[0009] Hence, small molecule inhibitors of c-FMS kinase, c-KIT kinase, or PDGFR kinases provide a rational approach to new therapies for the treatment of autoimmune diseases, and to particularly block the chronic tissue destruction mediated by the innate immune system. Inhibition of c-FMS kinase also provides a rational approach to new therapies for the treatment of cancers, especially for the treatment of cancer invasiveness, cancer angiogenesis or vasculogenesis, cancer metastasis, cancer immunotolerance, and for the treatment of cancers prone to bone metastases.

[0010] There is a need to provide kinase inhibitors which selectively inhibit kinases causative of the chronic tissue destruction in autoimmune disease (c-FMS, c-KIT, PDGFR), without inhibiting other kinases targeted by marketed cancer therapeutics (ABL, BCR-ABL, KDR, SRC, LCK, LYN, FGFR and other kinases). The present invention discloses novel inhibitors that inhibit c-FMS, c-KIT, and/or PDGFR kinases for the treatment of autoimmune diseases which also exhibit selectivity by not potently inhibiting other kinases including ABL, BCR-ABL, KDR, SRC, LCK, LYN, FGFR, MET and other kinases. The inhibitors of the present invention also find utility in the treatment of other mammalian diseases, including human diseases, mediated by c-FMS, c-KIT, or PDGFR kinases. Such diseases include, without limitation, cancers, autoimmune diseases, and bone resorptive diseases.

Summary

[0011] In one aspect, the present disclosure provides compounds of the Formula I:




Formula I

and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, wherein

A is taken from the group consisting of $-N(R_2)R_3$ and G;

G is selected from the group consisting of



and wherein the symbol (**) is the point of attachment to the pyrimidine ring;

each G moiety may be further substituted with one, two, or three R₄ moieties;

W is C₅-C₆heteroaryl, phenyl, $-NHC(O)R_6$, $-NHC(O)R_7$, $-NHC(O)N(R_8)R_9$ or $-C(O)N(R_8)R_9$, and wherein each C₅-C₆heteroaryl or phenyl is optionally substituted by one, two, or three R₅ moieties;

X₁ and X₂ are individually and independently hydrogen or C₁-C₆ alkyl;

R₁ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, or branched C₃-C₈ alkyl;

R₂ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, branched C₃-C₈ alkyl, C₃-C₈ cycloalkyl, fluoroC₁-C₆alkyl wherein the alkyl is fully or partially fluorinated, $-(CH_2)_m-OR_8$, or a 3-8 membered heterocyclic ring, wherein each alkylene is optionally substituted with C₁-C₄ alkyl;

R₃ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, branched C₃-C₈ alkyl, C₃-C₈ cycloalkyl, fluoroC₁-C₆alkyl wherein the alkyl is fully or partially fluorinated or a 3-8 membered heterocyclic ring;


each R₄ is individually and independently hydrogen, halogen, C₁-C₆ alkyl, fluoro-C₁-C₆ alkyl wherein the alkyl chain is partially or completely fluorinated, branched C₃-C₈

alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, $-(CH_2)_m-R_7$, or cyano, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R_5 is individually and independently hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, halogen, cyano, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, $-(CH_2)_m-C(O)NR_8(R_9)$, $-(CH_2)_m-C(O)R_7$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R_6 is individually and independently hydrogen, C1-C6 alkyl, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-CN$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R_7 is independently and individually selected from the group consisting of



and wherein the symbol (##) is the point of attachment to respective W, R_5 or R_6 moieties containing a R_7 moiety;

each R_7 is optionally substituted with $-(R_{10})_p$;

each R_8 and R_9 is individually and independently hydrogen, C1-C6 alkyl, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, or branched C3-C8 alkyl;


each R_{10} is individually and independently C1-C6 alkyl, $-(CH_2)_m-CN$, $-(CH_2)_m-OR_3$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-C(O)-R_6$, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl;

wherein each alkylene is optionally substituted with C1-C4 alkyl

each m is individually and independently 0, 1, 2, or 3; and

each p is 0, 1, 2, or 3.

[0011a] A compound of **Formula I**,




Formula I

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein

A is taken from the group consisting of $-N(R_2)R_3$ and G;

G is selected from the group consisting of



and wherein the symbol (**) is the point of attachment to the pyrimidine ring;

each G moiety may be further substituted with one, two, or three R_4 moieties;

W is C5-C6heteroaryl, phenyl, $-NHC(O)R_6$, $-NHC(O)R_7$, $-NHC(O)N(R_8)R_9$ or $-C(O)N(R_8)R_9$, and wherein each C5-C6heteroaryl or phenyl is optionally substituted by one, two, or three R_5 moieties;

X_1 and X_2 are individually and independently hydrogen or C1-C6 alkyl;

R_1 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl;

R_2 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated, $-(CH_2)_m-OR_8$, or a 3-8 membered non-aromatic heterocycle, wherein each alkylene is optionally substituted with C1-C4 alkyl;


R_3 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated or a 3-8 membered non-aromatic heterocycle;

each R_4 is individually and independently hydrogen, halogen, C1-C6 alkyl, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, $-(CH_2)_m-R_7$, or cyano, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R_5 is individually and independently hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, halogen, cyano, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, $-(CH_2)_m-C(O)NR_8(R_9)$, $-(CH_2)_m-C(O)R_7$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl;

Each R6 is individually and independently hydrogen, C1-C6 alkyl, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-CN$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R7 is independently and individually selected from the group consisting of



and wherein the symbol (##) is the point of attachment to respective W, R5 or R6 moieties containing a R7 moiety;

each R7 is optionally substituted with $-(R_{10})_p$;

each R8 and R9 is individually and independently hydrogen, C1-C6 alkyl, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, or branched C3-C8 alkyl;

each R10 is individually and independently C1-C6 alkyl, $-(CH_2)_m-CN$, $-(CH_2)_m-OR_3$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-C(O)-R_6$, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl;

wherein each alkylene is optionally substituted with C1-C4 alkyl

each m is individually and independently 0, 1, 2, or 3; and

each p is 0, 1, 2, or 3.

[0012] In one embodiment of Formula I, A is $-N(R_2)R_3$.


[0013] In one embodiment of Formula I, A is G.

[0014] In one embodiment of Formula I, W is C5-C6heteroaryl optionally substituted by one, two, or three R5.

[0015] In one embodiment of Formula I, W is $-NHC(O)R_6$, $-NHC(O)R_7$, or $-NHC(O)N(R_8)R_9$.

[0016] In one embodiment of Formula I, W is $-NHC(O)R_6$.

- [0017] In one embodiment of Formula I, W is -NHC(O)R_7 .
- [0018] In one embodiment of Formula I, W is $\text{-NHC(O)N(R}_8\text{)R}_9$.
- [0019] In one embodiment of Formula I, W is $\text{-C(O)N(R}_8\text{)R}_9$.
- [0020] In one embodiment of Formula I, W is phenyl optionally substituted by one, two, or three R_5 .
- [0021] In one embodiment of Formula I, X_1 and X_2 are individually and independently hydrogen or C1-C6 alkyl.
- [0022] In one embodiment of Formula I, X_1 and X_2 are hydrogen.
- [0023] In one embodiment of Formula I, one of X_1 and X_2 is hydrogen and the other is C1-C6alkyl.
- [0024] In one embodiment of Formula I, R_1 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl.
- [0025] In one embodiment of Formula I, R_1 is hydrogen.
- [0026] In one embodiment of Formula I, R_1 is C1-C6alkyl.
- [0027] In one embodiment, the compound of Formula I is a compound of Formula Ia wherein: W is C5-C6heteroaryl, phenyl, -NHC(O)R_6 , -NHC(O)R_7 , $\text{-NHC(O)N(R}_8\text{)R}_9$ or $\text{-C(O)N(R}_8\text{)R}_9$, and wherein each C5-C6heteroaryl or phenyl is optionally substituted by one, two, or three R_5 moieties; or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.



Formula Ia

- [0028] In one embodiment of Formula Ia, W is C5-C6heteroaryl optionally substituted by one, two, or three R_5 .
- [0029] In one embodiment of Formula Ia, W is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, or pyridinyl and wherein each W is optionally substituted by one, two, or three R_5 .
- [0030] In one embodiment of Formula Ia, W is pyrazolyl optionally substituted by one, two, or three R_5 .

- [0031] In one embodiment of Formula Ia, W is imidazolyl optionally substituted by one, two, or three R5.
- [0032] In one embodiment of Formula Ia, W is isoxazolyl optionally substituted by one or two R5.
- [0033] In one embodiment of Formula Ia, W is oxazolyl optionally substituted by one or two R5.
- [0034] In one embodiment of Formula Ia, W is thiazolyl optionally substituted by one or two R5.
- [0035] In one embodiment of Formula Ia, W is triazolyl optionally substituted by one or two R5.
- [0036] In one embodiment of Formula Ia, W is pyridinyl optionally substituted by one, two, or three R5.
- [0037] In one embodiment of Formula Ia, W is -NHC(O)R_6 , -NHC(O)R_7 , or $\text{-NHC(O)N(R}_8\text{)R}_9$.
- [0038] In one embodiment of Formula Ia, W is -NHC(O)R_6 .
- [0039] In one embodiment of Formula Ia, W is -NHC(O)R_7 .
- [0040] In one embodiment of Formula Ia, W is $\text{-NHC(O)N(R}_8\text{)R}_9$.
- [0041] In one embodiment of Formula Ia, W is $\text{-C(O)N(R}_8\text{)R}_9$.
- [0042] In one embodiment of Formula Ia, W is phenyl optionally substituted by one, two, or three R5.
- [0043] In one embodiment of Formula Ia, X1 and X2 are individually and independently hydrogen or C1-C6 alkyl.
- [0044] In one embodiment of Formula Ia, X1 and X2 are hydrogen.
- [0045] In one embodiment of Formula Ia, one of X1 and X2 is hydrogen and the other is C1-C6alkyl.
- [0046] In one embodiment of Formula Ia, R1 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl.
- [0047] In one embodiment of Formula Ia, R1 is hydrogen.
- [0048] In one embodiment of Formula Ia, R1 is C1-C6alkyl.
- [0049] In one embodiment of Formula Ia, R2 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated, –

$(\text{CH}_2)_m\text{-OR}_8$, or a 3-8 membered heterocyclic ring, wherein each alkylene is optionally substituted with C1-C4 alkyl.

[0050] In one embodiment of Formula Ia, R2 is C1-C6 alkyl, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(\text{CH}_2)_m\text{-OR}_8$, or a 3-8 membered heterocyclic ring, wherein each alkylene is optionally substituted with C1-C4 alkyl.

[0051] In one embodiment of Formula Ia, R2 is C1-C6 alkyl.

[0052] In one embodiment of Formula Ia, R2 is branched C3-C8 alkyl.

[0053] In one embodiment of Formula Ia, R2 is C3-C8 cycloalkyl.

[0054] In one embodiment of Formula Ia, R2 is $-(\text{CH}_2)_m\text{-OR}_8$, wherein each alkylene is optionally substituted with C1-C4 alkyl.

[0055] In one embodiment of Formula Ia, R2 is a 3-8 membered heterocyclic ring.

[0056] In one embodiment of Formula Ia, R3 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated or a 3-8 membered heterocyclic ring.

[0057] In one embodiment of Formula Ia, R3 is hydrogen.


[0058] In one embodiment of Formula Ia, R3 is C1-C6 alkyl.

[0059] In one embodiment of Formula Ia, R1 is hydrogen, R2 is C1-C6alkyl, branched C3-C8 alkyl or C3-C8 cycloalkyl, and R3 is hydrogen.

[0060] In one embodiment of Formula Ia, R1 is C1-C6alkyl, R2 is C1-C6alkyl, branched C3-C8 alkyl or C3-C8 cycloalkyl and R3 is hydrogen.

[0061] In one embodiment of Formula Ia, R1 is methyl, R2 is C1-C6alkyl, branched C3-C8 alkyl or C3-C8 cycloalkyl, and R3 is hydrogen.

[0062] In one embodiment, the compound of Formula I is a compound of Formula Ib wherein: X1 and X2 are individually and independently hydrogen or C1-C6 alkyl; or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.



Formula Ib


- [0063] In one embodiment of Formula Ib, X1 and X2 are hydrogen.
- [0064] In one embodiment of Formula Ib, one of X1 and X2 is hydrogen and the other is C1-C6alkyl.
- [0065] In one embodiment of Formula Ib, R1 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl.
- [0066] In one embodiment of Formula Ib, R1 is hydrogen.
- [0067] In one embodiment of Formula Ib, R1 is C1-C6alkyl.
- [0068] In one embodiment of Formula Ib, R2 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated, $-(CH_2)_m-OR_8$, or a 3-8 membered heterocyclic ring, wherein each alkylene is optionally substituted with C1-C4 alkyl.
- [0069] In one embodiment of Formula Ib, R2 is C1-C6 alkyl, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-OR_8$, or a 3-8 membered heterocyclic ring, wherein each alkylene is optionally substituted with C1-C4 alkyl.
- [0070] In one embodiment of Formula Ib, R2 is C1-C6 alkyl.
- [0071] In one embodiment of Formula Ib, R2 is branched C3-C8 alkyl.
- [0072] In one embodiment of Formula Ib, R2 is C3-C8 cycloalkyl.
- [0073] In one embodiment of Formula Ib, R2 is $-(CH_2)_m-OR_8$, wherein each alkylene is optionally substituted with C1-C4 alkyl.
- [0074] In one embodiment of Formula Ib, R2 is a 3-8 membered heterocyclic ring.
- [0075] In one embodiment of Formula Ib, R1 is hydrogen, and R2 is C1-C6alkyl, branched C3-C8 alkyl or C3-C8 cycloalkyl.
- [0076] In one embodiment of Formula Ib, R1 is C1-C6alkyl, and R2 is C1-C6alkyl, branched C3-C8 alkyl or C3-C8 cycloalkyl.
- [0077] In one embodiment of Formula Ib, R1 is methyl, and R2 is C1-C6alkyl, branched C3-C8 alkyl or C3-C8 cycloalkyl.
- [0078] In one embodiment of Formula Ib, R5 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, halogen, cyano, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, $-(CH_2)_m-C(O)NR_8(R_9)$, $-(CH_2)_m-C(O)R_7$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl.

[0079] In one embodiment of Formula Ib, R5 is hydrogen, C1-C6 alkyl, or deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl.

[0080] In one embodiment of Formula Ib, R5 is C1-C6 alkyl, or deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated.

[0081] In one embodiment of Formula Ib, R5 is C1-C6 alkyl.

[0082] In one embodiment, the compound of Formula I is a compound of Formula Ic wherein: W is C5-C6heteroaryl, phenyl, -NHC(O)R6, -NHC(O)R7, -NHC(O)N(R8)R9 or -C(O)N(R8)R9, and wherein each C5-C6heteroaryl or phenyl is optionally substituted by one, two, or three R5 moieties; or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.



Formula Ic

[0083] In one embodiment of Formula Ic, W is C5-C6heteroaryl optionally substituted by one, two, or three R5.

[0084] In one embodiment of Formula Ic, W is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, or pyridinyl and wherein each W is optionally substituted by one, two, or three R5.


[0085] In one embodiment of Formula Ic, W is pyrazolyl optionally substituted by one, two, or three R5.

[0086] In one embodiment of Formula Ic, W is imidazolyl optionally substituted by one, two, or three R5.

[0087] In one embodiment of Formula Ic, W is isoxazolyl optionally substituted by one or two R5.

[0088] In one embodiment of Formula Ic, W is oxazolyl optionally substituted by one or two R5.


- [0089] In one embodiment of Formula Ic, W is thiazolyl optionally substituted by one or two R⁵.
- [0090] In one embodiment of Formula Ic, W is triazolyl optionally substituted by one or two R⁵.
- [0091] In one embodiment of Formula Ic, W is pyridinyl optionally substituted by one, two, or three R⁵.
- [0092] In one embodiment of Formula Ic, W is –NHC(O)R₆, –NHC(O)R₇, or –NHC(O)N(R₈)R₉.
- [0093] In one embodiment of Formula Ic, W is –NHC(O)R₆.
- [0094] In one embodiment of Formula Ic, W is –NHC(O)R₇.
- [0095] In one embodiment of Formula Ic, W is –NHC(O)N(R₈)R₉.
- [0096] In one embodiment of Formula Ic, W is –C(O)N(R₈)R₉.
- [0097] In one embodiment of Formula Ic, W is phenyl optionally substituted by one, two, or three R⁵.
- [0098] In one embodiment of Formula Ic, X₁ and X₂ are individually and independently hydrogen or C₁-C₆ alkyl.
- [0099] In one embodiment of Formula Ic, X₁ and X₂ are hydrogen.
- [0100] In one embodiment of Formula Ic, one of X₁ and X₂ is hydrogen and the other is C₁-C₆alkyl.
- [0101] In one embodiment of Formula Ic, R₁ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, or branched C₃-C₈ alkyl.
- [0102] In one embodiment of Formula Ic, R₁ is hydrogen.
- [0103] In one embodiment of Formula Ic, R₁ is C₁-C₆alkyl.
- [0104] In one embodiment of Formula Ic, G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R₄ moieties.


- [0105] In one embodiment of Formula Ic, R₁ is hydrogen and G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R₄ moieties.


[0106] In one embodiment of Formula Ic, R₁ is C₁-C₆alkyl and G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R₄ moieties.


[0107] In one embodiment of Formula Ic, R₁ is methyl and G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R₄ moieties.

[0108] In one embodiment, the compound of Formula I is a compound of Formula Id wherein: X₁ and X₂ are individually and independently hydrogen or C₁-C₆ alkyl; or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.



Formula Id

[0109] In one embodiment, the compound of Formula Id is a compound wherein: X1 and X2 are hydrogen.


[0110] In one embodiment, the compound of Formula Id is a compound wherein: one of X1 and X2 is hydrogen and the other is C1-C6alkyl.

[0111] In one embodiment, the compound of Formula Id is a compound wherein: R1 is hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl.

[0112] In one embodiment, the compound of Formula Id is a compound wherein: R1 is hydrogen.

[0113] In one embodiment, the compound of Formula Id is a compound wherein: R1 is C1-C6alkyl.


[0114] In one embodiment, the compound of Formula Id is a compound wherein: G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R4 moieties.


[0115] In one embodiment, the compound of Formula Id is a compound wherein: R1 is hydrogen and G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R4 moieties.


[0116] In one embodiment, the compound of Formula Id is a compound wherein: R1 is C1-C6alkyl and G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R₄ moieties.

[0117] In one embodiment, the compound of Formula Id is a compound wherein: R₁ is methyl and G is selected from the group consisting of



wherein the symbol (**) is the point of attachment to the pyrimidine ring;

and wherein each G moiety may be further substituted with one, two, or three R₄ moieties.

[0118] In one embodiment, the compound of Formula Id is a compound wherein: R₅ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, branched C₃-C₈ alkyl, halogen, cyano, fluoro-C₁-C₆ alkyl wherein the alkyl chain is partially or completely fluorinated, $-(CH_2)_m-C(O)NR_8(R_9)$, $-(CH_2)_m-C(O)R_7$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C₁-C₄ alkyl.

[0119] In one embodiment, the compound of Formula Id is a compound wherein: R₅ is hydrogen, C₁-C₆ alkyl, or deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, or branched C₃-C₈ alkyl.

[0120] In one embodiment, the compound of Formula Id is a compound wherein: R₅ is C₁-C₆ alkyl, or deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated.

[0121] In one embodiment, the compound of Formula Id is a compound wherein: R₅ is C₁-C₆ alkyl.

[0122] In another aspect, the present disclosure provides a compound selected from the group consisting of 2-(ethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(dimethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-

one, 2-(ethylamino)-5-(6-methyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(6-methyl-5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-((2-methoxyethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylamino)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 4-((6-(2-(isopropylamino)-6-oxo-1,6-dihydropyrimidin-5-yl)pyridin-3-yl)oxy)-N-methylpicolinamide, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-morpholinopyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(piperidin-1-yl)pyrimidin-4(3H)-one, 2-(cyclopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(cyclopentylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 2-(cyclopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, N-(4-((6-(2-(isopropylamino)-6-oxo-1,6-dihydropyrimidin-5-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)acetamide, 5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 5-(5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-methylpyridin-2-yl)-2-(isopropylamino)pyrimidin-4(3H)-one, (R)-2-((1-methoxypropan-2-yl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, (R)-2-(2-(methoxymethyl)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, (S)-2-(3-(dimethylamino)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-((2-methoxyethyl)amino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-((tetrahydro-2H-

pyran-4-yl)amino)pyrimidin-4(3H)-one, 2-(tert-butylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(neopentylamino)pyrimidin-4(3H)-one, and 2-(3,3-difluoropyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.

[0122a] In a further aspect, the present disclosure provides a compound 2-(ethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.

[0122b] In another aspect, the present disclosure provides a compound 2-(isopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.

[0122c] In a further aspect, the present disclosure provides a compound 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.

[0123] In certain embodiments, the present disclosure comprises a method of treating mammalian disease at least partially mediated by the kinase activity of c-FMS, PDGFR- β , or c-KIT kinases, wherein the kinase is a wildtype form, a mutant oncogenic form, an aberrant fusion protein form or a polymorph thereof, the method comprising administering to a mammal in need thereof an effective amount of a compound of formula I.

[0123a] In one aspect, the present disclosure provides a pharmaceutical composition, comprising a compound as disclosed herein and a pharmaceutically acceptable carrier.

[0124] In other embodiments, the present disclosure comprises a pharmaceutical composition, comprising a compound of formula I and a pharmaceutically acceptable carrier.

[0125] In certain embodiments, the composition comprises an additive selected from adjuvants, excipients, diluents, or stabilizers.

[0126] In some embodiments, the present disclosure includes a method of treating cancer, gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, solid tumors, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic

cancers, osteosarcomas, multiple myelomas, cervical carcinomas, metastasis of primary tumor sites, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, osteoporosis, mastocytosis, or mast cell leukemia, the method comprising administering to a patient in need thereof an effective amount of a compound of formula I.

[0127] In some embodiments, the present disclosure includes a method of treating glioblastomas, breast cancers, pancreatic cancers, metastasis of primary tumor sites, or cancers that are metastatic to bone, the method comprising administering to a patient in need thereof an effective amount of a compound of formula I.

[0128] In certain embodiments of the present methods, the compound is administered orally, parenterally, by inhalation, or subcutaneously.

[0129] In some embodiments, the present disclosure provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the treatment of cancer, gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases,

solid tumors, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, metastasis of primary tumor sites, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, osteoporosis, mastocytosis, or mast cell leukemia, the method comprising administering to a patient in need thereof an effective amount of a compound of formula I.

[0130] In some embodiments, the present disclosure provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the treatment of glioblastomas, breast cancers, pancreatic cancers, metastasis of primary tumor sites, or cancers that are metastatic to bone, the method comprising administering to a patient in need thereof an effective amount of a compound of formula I.

[0130a] In one aspect, the present disclosure provides a use of a compound as disclosed herein in the manufacture of a medicament for the treatment of melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, or osteoporosis.

[0131] In some embodiments, the present disclosure provides for the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer, gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, solid tumors, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, metastasis of primary tumor sites, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, osteoporosis, mastocytosis, or mast cell leukemia.

[0131a] In one aspect, the present disclosure provides a use of a compound as disclosed herein in the manufacture of a medicament for the treatment of glioblastomas, breast cancers, pancreatic cancers or cancers that are metastatic to bone.

[0132] In certain embodiments, the present disclosure provides for the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of glioblastomas, breast cancers, pancreatic cancers, metastasis of primary tumor sites, or cancers that are metastatic to bone.

[0132a] In one aspect, the present disclosure provides a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, or osteoporosis.

[0132b] In another aspect, the present disclosure provides a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of glioblastomas, breast cancers, pancreatic cancers or cancers that are metastatic to bone.

[0133] The details of the invention are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined

otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0134] Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications and this disclosure.

[0135] For convenience, certain terms employed in the specification, examples and claims are collected here. Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The initial definition provided for a group or term provided in this disclosure applies to that group or term throughout the present disclosure individually or as part of another group, unless otherwise indicated.

[0136] The compounds of this disclosure include any and all possible isomers, stereoisomers, enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts. Thus, the terms “compound”, “compounds”, “test compound” or “test compounds” as used in this disclosure refer to the compounds of this disclosure and any and all possible isomers, stereoisomers, enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof.

Definitions

[0137] The term “alkyl” as used herein refers to a straight chain alkyl, wherein alkyl chain length is indicated by a range of numbers. In exemplary embodiments, “alkyl” refers to an alkyl chain as defined above containing 1, 2, 3, 4, 5, or 6 carbons (*i.e.*, C1-C6 alkyl). Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, and hexyl.

[0138] The term “branched alkyl” as used herein refers to an alkyl chain wherein a branching point in the chain exists, and the total number of carbons in the chain is indicated by a range of numbers. In exemplary embodiments, “branched alkyl” refers to an alkyl chain as defined above containing from 3, 4, 5, 6, 7, or 8 carbons (*i.e.*, branched C3-C8 alkyl). Examples of a branched alkyl group include, but are not limited to, *iso*-propyl, *iso*-butyl, *secondary*-butyl, and *tertiary*-butyl, 2-pentyl, 3-pentyl, 2-hexyl, and 3-hexyl.

[0139] The term “alkoxy” as used herein refers to $-O-(\text{alkyl})$, wherein “alkyl” is as defined above.

[0140] The term “branched alkoxy” as used herein refers to $-O-(\text{branched alkyl})$, wherein “branched alkyl” is as defined above.

[0141] The term “alkylene” as used herein refers to an alkyl moiety interposed between two other atoms. In exemplary embodiments, “alkylene” refers to an alkyl moiety as defined above containing 1, 2, or 3 carbons. Examples of an alkylene group include, but are not limited to $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, and $-\text{CH}_2\text{CH}_2\text{CH}_2-$. In exemplary embodiments, alkylene groups are branched.

[0142] The term “alkynyl” as used herein refers to a carbon chain containing one carbon-carbon triple bond. In exemplary embodiments, “alkynyl” refers to a carbon chain as described above containing 2 or 3 carbons (*i.e.*, C2-C3 alkynyl). Examples of an alkynyl group include, but are not limited to, ethyne and propyne.

[0143] The term “aryl” as used herein refers to a cyclic hydrocarbon, where the ring is characterized by delocalized π electrons (aromaticity) shared among the ring members, and wherein the number of ring atoms is indicated by a range of numbers. In exemplary embodiments, “aryl” refers to a cyclic hydrocarbon as described above containing 6, 7, 8, 9, or 10 ring atoms (*i.e.*, C6-C10 aryl). Examples of an aryl group include, but are not limited to, benzene, naphthalene, tetralin, indene, and indane.

[0144] The term “cycloalkyl” as used herein refers to a monocyclic saturated carbon ring, wherein the number of ring atoms is indicated by a range of numbers. In exemplary embodiments, “cycloalkyl” refers to a carbon ring as defined above containing 3, 4, 5, 6, 7, or 8 ring atoms (*i.e.*, C3-C8 cycloalkyl). Examples of a cycloalkyl group include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0145] The term “halogen” or “halo” as used herein refers to fluorine, chlorine, bromine, and iodine.

[0146] The term “heterocycle” or “heterocyclyl” as used herein refers to a cyclic hydrocarbon, wherein at least one of the ring atoms is an O, N, or S, wherein the number of ring atoms is indicated by a range of numbers. Heterocyclyl moieties as defined herein have C or N bonding hands through which the heterocyclyl ring is connected to an adjacent moiety. For example, in some embodiments, a ring N atom from the heterocyclyl is the bonding atom of the heterocyclic moiety. In exemplary embodiments, “heterocyclyl” refers to a monocyclic hydrocarbon containing 4, 5, 6, 7 or 8 ring atoms (*i.e.*, C4-C8 heterocyclyl).

Examples of a heterocycle group include, but are not limited to, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, pyran, thiopyran, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S-dioxide, oxazoline, tetrahydrothiophene, piperidine, tetrahydropyran, thiane, imidazolidine, oxazolidine, thiazolidine, dioxolane, dithiolane, piperazine, oxazine, dithiane, and dioxane.

[0147] The term “heteroaryl” as used herein refers to a cyclic hydrocarbon, where at least one of the ring atoms is an O, N, or S, the ring is characterized by delocalized π electrons (aromaticity) shared among the ring members, and wherein the number of ring atoms is indicated by a range of numbers. Heteroaryl moieties as defined herein have C or N bonding hands through which the heteroaryl ring is connected to an adjacent moiety. For example, in some embodiments, a ring N atom from the heteroaryl is the bonding atom of the heteroaryl moiety. In exemplary embodiments, “heteroaryl” refers to a cyclic hydrocarbon as described above containing 5 or 6 ring atoms (*i.e.*, C5-C6 heteroaryl). Examples of a heteroaryl group include, but are not limited to, pyrrole, furan, thiene, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyridazine, and triazine.

[0148] The term “substituted” in connection with a moiety as used herein refers to a further substituent which is attached to the moiety at any acceptable location on the moiety. Unless otherwise indicated, moieties can bond through a carbon, nitrogen, oxygen, sulfur, or any other acceptable atom.

[0149] The term “salts” as used herein embraces pharmaceutically acceptable salts commonly used to form alkali metal salts of free acids and to form addition salts of free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Exemplary pharmaceutical salts are disclosed in Stahl, P.H., Wermuth, C.G., Eds. *Handbook of Pharmaceutical Salts: Properties, Selection and Use*; Verlag Helvetica Chimica Acta/Wiley-VCH: Zurich, 2002, the contents of which are hereby incorporated by reference in their entirety. Specific non-limiting examples of inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids include, without limitation, aliphatic, cycloaliphatic, aromatic, arylaliphatic, and heterocyclyl containing carboxylic acids and sulfonic acids, for example formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic,

salicylic, *p*-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, 3-hydroxybutyric, galactaric or galacturonic acid. Suitable pharmaceutically acceptable salts of free acid-containing compounds disclosed herein include, without limitation, metallic salts and organic salts. Exemplary metallic salts include, but are not limited to, appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts, and other physiological acceptable metals. Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Exemplary organic salts can be made from primary amines, secondary amines, tertiary amines and quaternary ammonium salts, for example, tromethamine, diethylamine, tetra-*N*-methylammonium, *N,N'*-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (*N*-methylglucamine) and procaine.

[0150] The terms “administer,” “administering, or “administration” as used herein refer to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to a subject.

[0151] The term “carrier” as used herein encompasses carriers, excipients, and diluents, meaning a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ or portion of the body.

[0152] The term “disorder” is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

[0153] The terms “effective amount” and “therapeutically effective amount” are used interchangeably in this disclosure and refer to an amount of a compound that, when administered to a subject, is capable of reducing a symptom of a disorder in a subject. The actual amount which comprises the “effective amount” or “therapeutically effective amount” will vary depending on a number of conditions including, but not limited to, the particular disorder being treated, the severity of the disorder, the size and health of the patient, and the route of administration. A skilled medical practitioner can readily determine the appropriate amount using methods known in the medical arts.

[0154] The terms “isolated” and “purified” as used herein refer to a component separated from other components of a reaction mixture or a natural source. In certain embodiments, the isolate contains at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least

about 90%, at least about 95%, or at least about 98% of the compound or pharmaceutically acceptable salt of the compound by weight of the isolate.

[0155] The phrase “pharmaceutically acceptable” as used herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0156] As used in this disclosure, the terms “patient” or “subject” include, without limitation, a human or an animal. Exemplary animals include, but are not limited to, mammals such as mouse, rat, guinea pig, dog, feline, horse, cow, pig, monkey, chimpanzee, baboon, or rhesus monkey.

[0157] The terms "treatment," "treat," and "treating," are meant to include the full spectrum of intervention for the cancer from which the patient is suffering, such as administration of the active compound to alleviate, slow or reverse one or more of the symptoms and to delay progression of the cancer even if the cancer is not actually eliminated. Treating can be curing, improving, or at least partially ameliorating the disorder.

[0158] Structural, chemical and stereochemical definitions are broadly taken from IUPAC recommendations, and more specifically from Glossary of Terms used in Physical Organic Chemistry (IUPAC Recommendations 1994) as summarized by Müller, P. *Pure Appl. Chem.* **1994**, 66, pp. 1077-1184 and Basic Terminology of Stereochemistry (IUPAC Recommendations 1996) as summarized by Moss, G.P. *Pure Appl. Chem.* **1996**, 68, pp. 2193-2222.


[0159] Atropisomers are defined as a subclass of conformers which can be isolated as separate chemical species and which arise from restricted rotation about a single bond.

[0160] Regioisomers or structural isomers are defined as isomers involving the same atoms in different arrangements.

[0161] Enantiomers are defined as one of a pair of molecular entities which are mirror images of each other and non-superimposable.

[0162] Diastereomers or diastereoisomers are defined as stereoisomers other than enantiomers. Diastereomers or diastereoisomers are stereoisomers not related as mirror images. Diastereoisomers are characterized by differences in physical properties, and by some differences in chemical behavior towards achiral as well as chiral reagents.

[0163] The term “tautomer” as used herein refers to compounds produced by the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See March, *Advanced Organic Chemistry: Reactions, Mechanisms and Structures*, 4th Ed., John Wiley & Sons, pp. 69-74 (1992). Tautomerism is defined as isomerism of the general form



where the isomers (called tautomers) are readily interconvertible; the atoms connecting the groups X, Y and Z are typically any of C, H, O, or S, and G is a group which becomes an electrofuge or nucleofuge during isomerization. The most common case, when the electrofuge is H⁺, is also known as “prototropy.” Tautomers are defined as isomers that arise from tautomerism, independent of whether the isomers are isolable.

[0164] The exemplified compounds of the present invention are preferably formulated as a pharmaceutical composition using a pharmaceutically acceptable carrier and administered by a variety of routes. Preferably, such compositions are for oral administration. Such pharmaceutical compositions and processes for preparing them are well known in the art. *See, e.g.*, REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, *et al.*, eds., 19th ed., Mack Publishing Co., 1995).

[0165] The compounds of Formula I, or pharmaceutically acceptable salts thereof, may be prepared by a variety of procedures known in the art, as well as those described below. The specific synthetic steps may be combined in different ways to prepare the Formula I compounds, or a pharmaceutically acceptable salt thereof.

[0166] The compounds employed as initial starting materials in the synthesis of the compounds of Formula Ia are well known and, to the extent not commercially available, are readily synthesized using specific references provided, by standard procedures commonly employed by those of ordinary skill in the art, or are found in general reference texts.

[0167] Examples of known procedures and methods include those described in general reference texts such as *Comprehensive Organic Transformations*, VCH Publishers Inc, 1989; *Compendium of Organic Synthetic Methods*, Volumes 1-10, 1974-2002, Wiley Interscience; *Advanced Organic Chemistry, Reactions Mechanisms, and Structure*, 5th Edition, Michael B. Smith and Jerry March, Wiley Interscience, 2001; *Advanced Organic Chemistry*, 4th Edition, Part B, Reactions and Synthesis, Francis A. Carey and Richard J. Sundberg, Kluwer Academic / Plenum Publishers, 2000, etc., and references cited therein.

[0168] ChemDraw version 10 or 12 (CambridgeSoft Corporation, Cambridge, MA) was used to name the structures of intermediates and exemplified compounds.

[0169] The following abbreviations are used in this disclosure and have the following definitions: “ADP” is adenosine diphosphate “conc.” is concentrated, “DBU” is 1,8-diazabicyclo[5.4.0]undec-7-ene, “DCE” is 1,2-dichloroethane, “DCM” is dichloromethane, “DIEA” is *N,N*-diisopropylethylamine, “DMA” is *N,N*-dimethylacetamide, “DMAP” is 4-(dimethylamino)pyridine, “DMF” is *N,N*-dimethylformamide, “dppf” is 1,1'-bis(diphenylphosphino)ferrocene, “DMEM” is Dulbecco's Modified Eagle Media, “DMSO” is dimethylsulfoxide, “DPPA” is diphenylphosphoryl azide, “ESI” is electrospray ionization, “Et₂O” is diethylether, “EtOAc” is ethyl acetate, “EtOH” is ethanol, “GST” is glutathione S-transferase, “h” is hour or hours, “Hex” is hexane, “IC₅₀” is half maximal inhibitory concentration, “LiMHDS” is lithium bis(trimethylsilyl)amide, “mCPBA” is 3-chloroperbenzoic acid, “MeCN” is acetonitrile, “MeOH” is methanol, “Me₄tBuXPhos” is di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine, “MHz” is megahertz, “min” is minute or minutes, “MS” is mass spectrometry, “MTBE” is methyl *tert*-butyl ether, “NADH” is nicotinamide adenine dinucleotide, “NBS” is N-bromosuccinimide, “NMR” is nuclear magnetic resonance, “PBS” is phosphate buffered saline, “Pd/C” is palladium on carbon, “Pd₂(dba)₃” is tris(dibenzylideneacetone)dipalladium(0), “Pd(PPh₃)₄” is tetrakis(triphenylphosphine)palladium (0), “prep-HPLC” is preparative high performance liquid chromatography, “RT” is room temperature which is also known as “ambient temp,” which will be understood to consist of a range of normal laboratory temperatures ranging from 15-25 °C, “satd.” is saturated, “TEA” is triethylamine, “TFA” is trifluoroacetic acid, “THF” is tetrahydrofuran, “Tris” is tris(hydroxymethyl)aminomethane, “Xantphos” is 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, and “X-Phos” is 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.

General Chemistry

[0170] The compounds of Formula I are prepared by the general synthetic methods illustrated in the schemes below and the accompanying examples. Suitable reaction conditions for the steps of these schemes are well known in the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Those skilled in the art will understand that synthetic intermediates may be isolated and/or purified by well known techniques as needed or desired, and that it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, those skilled in the art will appreciate that in some instances, the order in which moieties are introduced is not critical. The particular order of steps required to produce the

compounds of Formula 1 is dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties, as is well appreciated by the ordinary skilled chemist. All substituents, unless otherwise indicated, are as defined above.


[0171] The compounds of Formula I may contain –NH or –OH moieties in the W and A positions. It will be understood by those skilled in the art that in some instances it may be advantageous to use an amine protecting group during synthesis to temporarily mask one or more –NH or –OH moieties. Said protecting group can be removed from any subsequent intermediate of the synthetic sequence, using standard conditions that effect removal of said protecting group, said conditions of which will be familiar to those skilled in the art. When not specified in a scheme, it will be understood by those skilled in the art that the W and A moieties represented in the schemes below may optionally contain standard amino or hydroxyl protecting groups that can be removed at any opportune time in the synthetic sequence.

[0172] Compounds 1 (Formula I wherein R1 is H) of the invention can be prepared as illustrated in Scheme 1. In one embodiment, the di-pyridine 2 can react with boronate 3 or boronic acid 4 to provide intermediate 5. The reaction of 2 with 3 or 4 is generally performed in the presence of a palladium catalyst, for example for example Pd(PPh₃)₄, and a base, for example potassium carbonate with heating. Further conversion of 5 to 7 is effected by reaction of 5 with reagent M-W (6), wherein M is trialkylstanyl or a boronic acid or boronate ester (when W is heteroaryl), or alternately wherein M is H (when W is –NHC(O)R₆, –NHC(O)R₇, –NHC(O)N(R₈)R₉). Conditions for the transformation of 5 to 7 are dependent on the nature of the W-moiety, but generally include the use of palladium catalysts, for example Pd(PPh₃)₄ or Pd₂(dba)₃, optionally in the presence of additional ligands, for example Xantphos. General conditions to accomplish these transformations are well known to those skilled in the art and are further illustrated in the accompanying examples. Finally, cleavage of the methyl ether of 7, for example by treatment with HBr or trimethylsilyl iodide, provides compounds of formula 1 wherein R1 is H.

[0173] In another embodiment of Scheme 1, compound 7 can be prepared directly from 8 (Z is bromo or iodo) by reaction with 3 or 4.

[0174] In another embodiment of Scheme 1, intermediate 7 can be prepared from 2 by a sequence commencing with the reaction of 2 with 9 or 10 to provide 11. Reaction of 11 with M-W (6) as described above provides 12. In another embodiment, reaction of 8 with 9 or 10


affords 12 directly. Reaction of 12 with amine A-H 13 provides 7. In one embodiment, the conversion of 12 to 7 is accomplished by sequential treatment with an oxidant, such as m-chloroperoxybenzoic acid, to effect the oxidation of the thiomethyl moiety of 12 to a methylsulfoxide or methylsulfone intermediate followed by treatment of said intermediate with A-H 13.



Scheme 1


[0175] Scheme 2 illustrates the preparation of compounds of formula 18 (Formula I wherein R1 is alkyl or branched alkyl). In a manner similar to Scheme 1, compound 2 can be

reacted with 14 or 15 and a palladium catalyst to afford 16. Further reaction of 16 with M-W (6) as described above provides 17. Intermediate 17 can also be prepared by the reaction of 8 (Z is bromo or iodo) with 14 or 15 and a palladium catalyst. Reaction of 17 with amine A-H (13) affords 18. In one embodiment, the thiomethyl moiety of 17 is oxidized to a methylsulfoxide or methylsulfone prior to treatment with amine A-H 13.




Scheme 2

[0176] General intermediate 2 is prepared as illustrated in Scheme 3. Treatment of hydroxypyridine 19 with iodine in the presence of a carbonate base affords iodide 20. Further treatment of 20 with 2,4-dichloropyridine (21) in the presence of a base, for example potassium carbonate, provides 2.




Scheme 3

[0177] General intermediate **8** is prepared as illustrated in Scheme 4. Thus, intermediate **22** (Y is halogen) is reacted with 2-chloro-4-hydroxypyridine (**23**) in the presence of a base, for example potassium carbonate to provide the nitro ether **24**. Reduction of the nitro moiety of **24** provides amine **25**. Conditions to effect the conversion of **24** to **25** are known by those skilled in the art and include the use of zinc powder in the presence of ammonium chloride in a protic solvent such as methanol. Further reaction of **25** with M-W (**6**) as described above provides **26**. In one embodiment, the order of steps for the conversion of **24** to **26** is reversed, such that **24** is first reacted with M-W **6**. The product of said reaction containing a nitro moiety is then reduced to provide **26**. Conversion of amine **26** to **8** is accomplished by conversion of the amino moiety of **26** to a diazonium salt and the in situ replacement of the diazonium moiety with halogen. Conditions to effect the transformation of **26** to **8** (Z is bromo) include treatment of a mixture of **26** and tetrabutylammonium bromide in dibromomethane with tert-butyl nitrite. Conditions to effect the transformation of **26** to **8** (Z is iodo) include treatment of a mixture of **26** and potassium iodide in diiodomethane with tert-butyl nitrite.



Scheme 4

[0178] Scheme 5 illustrates the synthesis of boronate esters/boronic acids 3/4, 9/10, and 14/15. In one embodiment of Scheme 5, chloro-pyrimidine 27 is reacted with amine A-H 13 to afford 28. Conditions for the transformation include combining 27 and 13 in a solvent, for example THF, and heating the mixture to effect the reaction. Further reaction of 28 with bis(pinacolato)diboron (34) in the presence of a palladium catalyst, for example PdCl₂(dppf), and a mild base, for example potassium acetate, with heating provides sensitive boronate 3 and/or boronic acid 4. In practice, it is not necessary to separate potential mixtures of 3 and 4 for further use and the product(s) of the reaction of 28 and 34 is typically used in a crude form, without further purification. In another embodiment, 29 and 34 are reacted under the same conditions to provide 9 and/or 10. In practice, the product(s) of the reaction of 29 and 34 can be used in a crude form, without further purification.




Scheme 5

[0179] In another embodiment of Scheme 5, pyrimidinone **30** can be alkylated with R1-X (**31**, X is halogen) to provide **32**. In one embodiment, said alkylation is effected by treatment

of 29 in a solvent, such as THF or DMF, with a strong base, for example lithium bis(trimethylsilyl)amide, followed by the addition of 31. Bromination of 32 provides 33. In one embodiment, the order of steps for the conversion of 30 to 33 is reversed, such that 30 is brominated prior to alkylation with R1-X 31. Finally, reaction of 33 with 34 provides boronate 14 and/or boronic acid 15. In practice, the product(s) of the reaction of 33 and 34 can be used in a crude form, without further purification.

[0180] General intermediate 38, an example 8 wherein W is -C(O)N(R8)R9, is prepared as illustrated in Scheme 6. Thus, hydroxypyridine 35 is reacted with chloropicolinamide 36 in the presence of a base, for example potassium tert-butoxide, to provide ether 37. Diazotization of the amino moiety of 37 in the presence of iodide affords iodopyridine 38.



Scheme 6


[0181] Using the synthetic procedures and methods described herein and methods known to those skilled in the art, the following compounds were made: 2-(ethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(dimethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(6-methyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(6-methyl-5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-((2-methoxyethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylamino)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 4-((6-(2-(isopropylamino)-

6-oxo-1,6-dihydropyrimidin-5-yl)pyridin-3-yl)oxy)-N-methylpicolinamide, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-morpholinopyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(piperidin-1-yl)pyrimidin-4(3H)-one, 2-(cyclopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(cyclopentylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 2-(cyclopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, N-(4-((6-(2-(isopropylamino)-6-oxo-1,6-dihydropyrimidin-5-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)acetamide, 5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 5-(5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-methylpyridin-2-yl)-2-(isopropylamino)pyrimidin-4(3H)-one, (R)-2-((1-methoxypropan-2-yl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, (R)-2-(2-(methoxymethyl)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, (S)-2-(3-(dimethylamino)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-((2-methoxyethyl)amino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4(3H)-one, 2-(tert-butylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(neopentylamino)pyrimidin-4(3H)-one, and 2-(3,3-difluoropyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.

Examples


[0182] The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to

be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.



Example A1: A solution of 3-hydroxy-2-methylpyridine (20.0 g, 183 mmol) and Na_2CO_3 (38.8 g, 367 mmol) in H_2O (320 mL) and MeOH (200 mL) was treated with I_2 (46.5 g, 183 mmol) and stirred at RT for 1 h. The mixture was acidified with HCl (2 M), extracted with EtOAc (2x) and the combined organics were washed with brine, dried over Na_2SO_4 and concentrated to dryness. The material was suspended in 1:1 EtOAc/Hex, sonicated and the solid collected via filtration and dried. The filtrate was concentrated to dryness, treated with DCM, the solid collected via filtration and combined with the first solid to afford 6-iodo-2-methylpyridin-3-ol (20.5 g, 48%). MS (ESI) m/z : 236.0 ($\text{M}+\text{H}^+$).

[0183] A mixture of 6-iodo-2-methylpyridin-3-ol (6.8 g, 28.9 mmol), 2,4-dichloropyridine (8.56 g, 57.9 mmol) and K_2CO_3 (4.00 g, 28.9 mmol) in DMA (50 mL) was heated at 110°C for 16 h under argon. The mixture was cooled to RT, treated with H_2O , extracted with EtOAc (2x) and the combined organics were washed with H_2O , then brine, dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (EtOAc/Hex) to afford 3-((2-chloropyridin-4-yl)oxy)-6-iodo-2-methylpyridine (7.35 g, 73 %) as a white solid. MS (ESI) m/z : 346.9 ($\text{M}+\text{H}^+$).




Example A2: A 0°C solution of H_2SO_4 (12 mL) was treated with H_2O_2 (9.72 mL, 95 mmol), stirred for 10 min, treated with a solution of 2-amino-5-fluoro-4-methylpyridine (2 g, 15.86 mmol) in H_2SO_4 (8 mL), stirred for 15 min, then warmed to RT and stirred for 3 h. The mixture was re-cooled to 0°C , neutralized slowly with solid NaHCO_3 and the resulting solid was collected by filtration and dried to afford 5-fluoro-4-methyl-2-nitropyridine (2 g, 81%).

^1H NMR (400 MHz, DMSO- d_6): δ 8.57 (s, 1 H), 8.42 (d, J = 5.3 Hz, 1 H), 2.42 (d, J = 1.9 Hz, 3 H); MS (ESI) m/z : 157.1 ($\text{M}+\text{H}^+$).


[0184] A mixture of 5-fluoro-4-methyl-2-nitropyridine (2 g, 12.81 mmol) and 2-chloro-4-hydroxypyridine (1.66 g, 12.81 mmol) in DMF (26 mL) was sparged with Ar, treated with K_2CO_3 (2.66 g, 19.22 mmol), heated at 88°C for 24 h, then at 50°C for 2 days. The mixture was treated with water and the resulting solid collected via filtration and dried to afford 5-((2-chloropyridin-4-yl)oxy)-4-methyl-2-nitropyridine (2.72 g, 80%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.49 (s, 1 H), 8.47 (s, 1 H), 8.35 (d, J = 5.7 Hz, 1 H), 7.24 (d, J = 2.3 Hz, 1 H), 7.12 (dd, J = 5.7, 2.3 Hz, 1 H), 2.32 (s, 3 H); MS (ESI) m/z : 266.0 ($\text{M}+\text{H}^+$).

[0185] A solution of 5-((2-chloropyridin-4-yl)oxy)-4-methyl-2-nitropyridine (1.5 g, 5.65 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.527 g, 7.34 mmol) in dioxane (20 mL) was sparged with Ar, treated with a solution of K_2CO_3 (1.171 g, 8.47 mmol) in water (5 mL) and $\text{Pd}(\text{PPh}_3)_4$ (0.326 g, 0.282 mmol) and heated at 80°C overnight. The mixture was cooled to RT, treated with water, extracted with DCM (4x) and the combined organics were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford 4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-2-nitropyridine (2.3 g, 75%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.48 (s, 1 H), 8.43-8.42 (m, 2 H), 8.27 (s, 1 H), 7.98 (s, 1 H), 7.30 (d, J = 2.4 Hz, 1 H), 6.83 (dd, J = 5.7, 2.4 Hz, 1 H), 3.84 (s, 3 H), 2.34 (s, 3 H); MS (ESI) m/z : 312.1 ($\text{M}+\text{H}^+$).


[0186] A solution of 4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-2-nitropyridine (2.3 g, 7.39 mmol) in MeOH (37 mL) and THF (37 mL) was treated with NH_4Cl (11.86 g, 222 mmol) followed by the portion-wise addition of zinc dust (4.83 g, 73.9 mmol) and the mixture stirred at RT overnight. The mixture was diluted with EtOAc, the solids removed via filtration through diatomaceous earth and the filtrate concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford 4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (1.4 g, 67%). MS (ESI) m/z : 282.1 ($\text{M}+\text{H}^+$).



Example A3: A solution of **Example A2** (0.2 g, 0.71 mmol) in dibromomethane (5 mL) was treated with tetrabutylammonium bromide (0.92 g, 2.84 mmol) and *t*-butylnitrite (0.7 g, 7.11 mmol) and stirred at RT for 4 h. The mixture was diluted with EtOAc, washed successively with satd. NaHCO₃, water, and brine, dried over Na₂SO₄ and concentrated to dryness to afford 2-bromo-4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine as off-white solid (0.21 g, 86%). MS (ESI) *m/z*: 345.1 (M+H⁺).



Example A4: A suspension of **Example A2** (0.62 g, 2.2 mmol), KI (3.7 g, 22.3 mmol), and diiodomethane (5 mL, 62 mmol) was treated with *t*-butylnitrite (1.4 mL, 11.7 mmol) and stirred at RT for 12 h. The mixture was treated with EtOAc, washed successively with satd. NaHCO₃ (3x), 10 % Na₂S₂O₃ (2x), and brine (2x) and the combined aqueous washes were back-extracted with EtOAc (2x). The combined organics were dried over MgSO₄, concentrated to dryness and purified by silica gel chromatography (EtOAc/DCM) to afford 2-iodo-4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine (0.51 g, 59%). MS (ESI) *m/z*: 393.0 (M+H⁺).




Example A5: A solution of 5-bromo-2-nitropyridine (15 g, 73.9 mmol) in DMF (300 mL) was sparged with Ar, treated with Cs₂CO₃ (48.2 g, 148 mmol) and 2-chloro-4-hydroxypyridine (10.53 g, 81 mmol), sparged again with Ar and heated at 85°C overnight. The mixture was cooled to RT, filtered through a bed of silica gel, washed thoroughly with EtOAc, and the filtrate treated with 5% LiCl and stirred overnight. The layers were separated, the aqueous layer extracted with additional EtOAc (4x) and the combined organics were dried over Na₂SO₄ and concentrated to dryness. The residue was dissolved in EtOAc, treated with 5% LiCl, stirred for 1 h, the layers separated and the aqueous layer extracted with EtOAc (3x). The combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (EtOAc/Hex). The material was suspended in MTBE, sonicated and the resulting solid collected via filtration to afford 2-chloro-4-((6-

nitropyridin-3-yl)oxy)pyridine (6.06 g, 33%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.62 (d, J = 2.4, 1 H), 8.43-8.39 (m, 2 H), 8.06 (dd, J = 8.8, 2.8 Hz, 1 H), 7.36 (d, J = 2.0 Hz, 1 H), 7.23 (dd, J = 5.6, 2.0 Hz, 1 H); MS (ESI) m/z : 252.0 ($\text{M}+\text{H}^+$).

[0187] A solution of 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (20.0 g, 79 mmol) in MeOH (40 mL) was hydrogenated in presence of Raney Nickel (2.00 g, 34.1 mmol) at 40 psi for 3 h. The catalyst was removed via filtration, rinsed with MeOH and the filtrate concentrated to dryness to afford 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (18.52 g, 105%) as a brown solid. MS (ESI) m/z : 222.0 ($\text{M}+\text{H}^+$).

[0188] A mixture of 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (1.00 g, 4.51 mmol) and potassium iodide (3.74 g, 22.5 mmol) in DCM (15 mL) was treated dropwise with *t*-butyl nitrite (4.65 g, 45.1 mmol) and the mixture was stirred overnight at RT. The mixture was diluted with EtOAc (75 mL) and washed with 10% Na_2CO_3 (50 mL), then water (50 mL) and finally brine (50 mL) and dried over sodium sulfate. The solvents were evaporated at reduced pressure to give a thick oily solution. EtOAc (100 mL) was added and the solution was washed with 0.1M sodium thiosulfate (75 mL), brine (50 mL) and dried over sodium sulfate. The solvents were evaporated at reduced pressure, and the residual oil was purified by silica gel chromatography to provide 2-chloro-4-((6-iodopyridin-3-yl)oxy)pyridine (695 mg, 46%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.80 (d, J = 3.0 Hz, 1 H), 8.73 (d, J = 5.8 Hz, 1 H), 8.35 (d, J = 8.6 Hz, 1 H), 7.91 (dd, J = 8.6, 3.1 Hz, 1 H), 7.61 (d, J = 2.3 Hz, 1 H), 7.48 (dd, J = 5.8, 2.3 Hz, 1 H).




Example A6: DMF (25 mL) was slowly treated with SOCl_2 (125 mL) to maintain a temperature of 40-50°C. The mixture was then treated portion-wise with pyridine-2-carboxylic acid (25 g, 0.2 mol) over 0.5 h, then heated at reflux for 16 h, cooled to RT, diluted with toluene (80 mL) and concentrated to dryness (this process was repeated three times). The resulting residue was washed with toluene and dried under reduced pressure to yield 4-chloro-pyridine-2-carbonyl chloride (27.6 g, 79% yield), which was used in the next step without purification.

[0189] A 0°C solution of 4-chloro-pyridine-2-carbonyl chloride (27.6 g, 0.16 mol) in THF (100 mL) was treated drop-wise with a solution of MeNH_2 in EtOH, stirred at 3°C for

4 h, then concentrated to dryness. The material was suspended in EtOAc, the solids removed via filtration and the filtrate was washed with brine (2x), dried and concentrated to yield 4-chloro-N-methylpicolinamide (16.4 g, 60%) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.78 (br s, 1H), 8.55 (d, J = 5.2 Hz, 1H), 7.97 (d, J = 2.0 Hz, 1H), 7.66 (m, 1H), 2.82 (d, J = 4.8 Hz, 3H); MS (ESI) m/z : 171.0 ($\text{M}+\text{H}^+$).

[0190] A solution of 2-amino-5-hydroxypyridine (0.968 g, 8.79 mmol) in DMA (15 mL) was treated with potassium tert-butoxide (0.987 g, 8.79 mmol), stirred at RT for 3 h, treated with 4-chloro-N-methylpicolinamide (1.5 g, 8.79 mmol) and stirred at RT for 2 days. The mixture was concentrated to dryness, treated with water, extracted with EtOAc (3x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (EtOAc, MeOH/DCM) to afford 4-((6-aminopyridin-3-yl)oxy)-N-methylpicolinamide (1.3 g, 61%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.75 (m, 1 H), 8.46 (d, J = 5.6 Hz, 1 H), 7.82 (d, J = 2.9 Hz, 1 H), 7.34 (d, J = 2.6 Hz, 1 H), 7.30 (dd, J = 8.9, 3.0 Hz, 1 H), 7.10 (dd, J = 5.6, 2.7 Hz, 1 H), 6.53 (d, J = 8.9 Hz, 1 H), 6.07 (s, 2 H), 2.77 (d, J = 4.8 Hz, 3 H); MS (ESI) m/z : 245.1 ($\text{M}+\text{H}^+$).


[0191] A mixture of 4-((6-aminopyridin-3-yl)oxy)-N-methylpicolinamide (0.4 g, 1.64 mmol) and potassium iodide (1.36 g, 8.19 mmol) in methylene iodide (5.46 mL) was treated dropwise with t-butyl nitrite (1.95 mL, 16.4 mmol). The mixture was stirred overnight at RT, diluted with EtOAc (75 mL), and washed with 10% sodium carbonate (50 mL), 10% thiosulfate (50 mL), and brine (50 mL). The organics were dried over sodium sulfate, evaporated to dryness and purified by silica gel chromatography ((EtOAc/Hex) to afford 4-((6-iodopyridin-3-yl)oxy)-N-methylpicolinamide (0.214 g, 36.8%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.78 (br d, J = 5.6 Hz, 1 H), 8.54 (d, J = 5.6 Hz, 1 H), 8.40 (d, J = 3.0 Hz, 1 H), 7.95 (d, J = 8.6 Hz, 1 H), 7.50 (dd, J = 8.6, 3.1 Hz, 1 H), 7.45 (d, J = 2.6 Hz, 1 H), 7.23 (dd, J = 5.6, 2.7 Hz, 1 H), 2.78 (d, J = 4.9 Hz, 3 H); MS (ESI) m/z : 356.0 ($\text{M}+\text{H}^+$).




Example B1: A solution of 5-bromo-2-chloro-4-methoxypyrimidine (0.6 g, 2.69 mmol) in THF (10 mL) was treated with ethylamine (2.0M in THF, 6.71 mL, 13.43 mmol) was heated at 60°C for 1 h, cooled to RT and diluted with water. The mixture was extracted with EtOAc

(2x) and the combined organics were washed with brine, dried over Na₂SO₄, concentrated to dryness and purified by column chromatography (EtOAc/Hex) to afford 5-bromo-N-ethyl-4-methoxypyrimidin-2-amine as a white solid (0.54 g, 87%). MS (ESI) *m/z*: 232.03 (M+H⁺).

[0192] A solution of 5-bromo-N-ethyl-4-methoxypyrimidin-2-amine (0.73 g, 3.15 mmol) in dioxane (25 mL) was sparged with Ar, treated with bis(pinacolato)diboran (1.04 g, 4.1 mmol), KOAc (0.62 g, 6.29 mmol), PdCl₂(dppf) (0.23 g, 0.315 mmol) and heated at 100°C for 20 h. The mixture was cooled to RT to afford a solution of crude (2-(ethylamino)-4-methoxypyrimidin-5-yl)boronic acid (50% yield assumed) which was used without further purification. MS (ESI) *m/z*: 198.1 (M+H⁺).




Example B2: A mixture of 5-bromo-4-methoxy-2-(methylthio)pyrimidine (1.0 g, 4.25 mmol), bis(pinacolato)diboran (1.30 g, 5.10 mmol), and KOAc (1.25 g, 12.76 mmol) in dioxane (10 mL) was sparged with Ar, treated with PdCl₂(dppf)-DCM adduct (0.17 g, 0.21 mmol), sparged again with Ar and heated at 85°C overnight. The mixture was cooled to RT, treated with satd. NaHCO₃, extracted with EtOAc (3x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (MeOH/EtOAc) to obtain (4-methoxy-2-(methylthio)pyrimidin-5-yl)boronic acid pinacol ester (100% yield assumed) which was used without further purification. MS (ESI) *m/z*: 201.1 (M+H⁺).



Example B3: A solution of 5-bromo-2-chloro-4-methoxypyrimidine (1.2 g, 5.37 mmol) in THF (20 mL) was treated with TEA (1.57 mL, 10.74 mmol) and isopropylamine (0.7 mL, 8.1 mmol) and heated at 60°C for 5 h. The mixture was cooled to RT, treated with water, extracted with EtOAc (2x) and the combined organics were washed with brine, dried over Na₂SO₄, concentrated to dryness and purified by silica gel chromatography (EtOAc/Hex) to afford 5-bromo-N-isopropyl-4-methoxypyrimidin-2-amine (0.84 g, 634%). ¹H NMR (400

MHz, DMSO- d_6): δ 8.10 (s, 1 H), 7.17 (br s, 1 H), 3.96-3.94 (m, 1 H), 3.87 (s, 3 H), 1.12 (d, $J = 6.5$ Hz, 6 H); MS (ESI) m/z : 246.0 ($M+H^+$).

[0193] A solution of 5-bromo-N-isopropyl-4-methoxypyrimidin-2-amine (0.84 g, 3.41 mmol) in dioxane (20 mL) was sparged with Ar, treated with bis(pinacolato)diboran (1.127 g, 4.44 mmol), KOAc (0.502 g, 5.12 mmol) and PdCl₂(dppf)-DCM adduct (0.279 g, 0.341 mmol) and heated at 95°C for 16 h. The mixture was cooled to RT and concentrated to dryness to afford crude N-isopropyl-4-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (60% yield assumed) which was used without further purification. MS (ESI) m/z : 212.1 ($M+H^+$) [ion for corresponding boronic acid].




Example B4: A 0°C suspension of 2-(methylthio)pyrimidin-4(3H)-one (2.0 g, 14.1 mmol) in DMF (40 mL) was treated with solid LiHMDS (3.06 g, 18.3 mmol), followed by methyl iodide (1.14 mL, 18.3 mmol), warmed to RT and stirred overnight. The mixture was quenched with water, extracted with EtOAc (3x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (EtOAc/Hex) to afford 3-methyl-2-(methylthio)pyrimidin-4(3H)-one (1.37 g, 62%). ¹H NMR (400 MHz, DMSO- d_6): δ 7.83 (d, $J = 6.5$ Hz, 1 H), 6.17 (d, $J = 6.5$ Hz, 1 H), 3.39 (s, 3 H), 2.54 (s, 3 H); MS (ESI) m/z : 157.1 ($M+H^+$).


[0194] A 0°C solution of 3-methyl-2-(methylthio)pyrimidin-4(3H)-one (1.37 g, 8.77 mmol) in CHCl₃ (15 mL) was treated with bromine (0.54 mL, 10.5 mmol), stirred at 0°C for 1 h, quenched with satd. NaHCO₃ (15 mL), warmed to RT slowly and stirred overnight. The mixture was extracted with DCM (3x) and the combined organics were dried over Na₂SO₄ and concentrated to dryness to afford 5-bromo-3-methyl-2-(methylthio)pyrimidin-4(3H)-one (2.0 g, 97% yield). ¹H NMR (400 MHz, DMSO- d_6): δ 8.24 (s, 1 H), 3.45 (s, 3 H), 2.55 (s, 3 H); MS (ESI) m/z : 235.0 ($M+H^+$).

[0195] A mixture of 5-bromo-3-methyl-2-(methylthio)pyrimidin-4(3H)-one (1.0 g, 4.25 mmol), bis(pinacolato)diboran (1.30 g, 5.10 mmol), and KOAc (1.25 g, 12.7 mmol) in dioxane (10 mL) was sparged with Ar, treated with PdCl₂(dppf)-DCM-adduct (0.17 g, 0.21 mmol), sparged again with Ar and heated at 85°C overnight. The mixture was cooled to RT,

quenched with satd. NaHCO_3 , extracted with EtOAc (3x) and the combined organics were dried over Na_2SO_4 and concentrated to dryness to afford 3-methyl-2-(methylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-4(3H)-one (100% yield assumed). MS (ESI) m/z : 202.1 (mass of boronic acid+ H^+).




Example C1: A solution of crude **Example B1** (0.310 g, 1.574 mmol) in dioxane (25 mL) was treated with a degassed solution of K_2CO_3 (0.65 g, 4.72 mmol) in water (4 mL), **Example A1** (0.55 g, 1.58 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (0.18 g, 0.16 mmol) and heated at 90°C for 16 h. The mixture was cooled to RT, diluted with water, extracted with EtOAc (3x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified by column chromatography (EtOAc/DCM) to afford 5-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-N-ethyl-4-methoxypyrimidin-2-amine (350 mg, 60%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.73 (s, 1 H), 8.29 (d, $J = 5.8$ Hz, 1 H), 7.77 (d, $J = 8.9$ Hz, 1 H), 7.61 (d, $J = 8.6$ Hz, 1 H), 7.38 (br s, 1 H), 7.06 (d, $J = 2.3$ Hz, 1 H), 6.94 (dd, $J = 5.8, 2.3$ Hz, 1 H), 4.01-3.91 (m, 3 H), 3.36-3.34 (m, 2 H), 2.33 (s, 3 H), 1.15 (t, $J = 7.4$ Hz, 3 H); MS (ESI) m/z : 372.1 ($\text{M}+\text{H}^+$).



Example C2: A mixture of **B2** (0.63 g, 2.25 mmol), **Example A1** (0.65 g, 1.88 mmol), and K_2CO_3 (0.78 g, 5.63 mmol) in 5:1 dioxane/ H_2O (6 mL) was sparged with Ar, treated with $\text{Pd}(\text{PPh}_3)_4$ (0.22 g, 0.19 mmol), sparged again with Ar and heated at 90°C overnight. The mixture was cooled to RT, treated with satd. NaHCO_3 , extracted with EtOAc (3x) and the combined organics were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (EtOAc/Hex) to obtain 5-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-4-methoxy-2-(methylthio)pyrimidine (0.49 g, 70%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.91 (s, 1 H), 8.31 (d, $J = 5.8$ Hz, 1 H), 7.89 (d, $J = 8.5$ Hz, 1 H), 7.72 (d,

$J = 8.5$ Hz, 1 H), 7.11 (d, $J = 2.3$ Hz, 1 H), 6.99 (dd, $J = 5.8, 2.3$ Hz, 1 H), 4.06 (s, 3 H), 2.58 (s, 3 H), 2.39 (s, 3 H); MS (ESI) m/z : 375.1 ($M+H^+$).


[0196] A mixture of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.30 g, 1.44 mmol), 5-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-4-methoxy-2-(methylthio)pyrimidine (0.49 g, 1.31 mmol), and K_2CO_3 (0.54 g, 3.92 mmol) in 5:1 dioxane/water (18 mL) was sparged with Ar, treated with $Pd(PPh_3)_4$ (0.15 g, 0.13 mmol), sparged again with Ar and heated at 90°C for 4 h. The mixture was cooled to RT, treated with satd. $NaHCO_3$, extracted with EtOAc (3x) and the combined organics were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylthio)pyrimidine (0.54 g, 98%). ^1H NMR (400 MHz, $DMSO-d_6$): δ 8.93 (s, 1 H), 8.39 (d, $J = 5.7$ Hz, 1 H), 8.28 (s, 1 H), 7.99 (d, $J = 0.7$ Hz, 1 H), 7.88 (d, $J = 8.5$ Hz, 1 H), 7.65 (d, $J = 8.6$ Hz, 1 H), 7.30 (d, $J = 2.4$ Hz, 1 H), 6.66 (dd, $J = 5.7, 2.4$ Hz, 1 H), 4.06 (s, 3 H), 3.85 (s, 3 H), 2.58 (s, 3 H), 2.42 (s, 3 H); MS (ESI) m/z : 421.1 ($M+H^+$).




Example C3: A mixture of **Example B4** (0.35 g, 1.73 mmol), **Example A1** (0.50 g, 1.44 mmol), and K_2CO_3 (0.60 g, 4.33 mmol) in 5: 1 dioxane/water (12 mL) was sparged with Ar, treated with $Pd(PPh_3)_4$ (0.17 g, 0.14 mmol), sparged again with Ar and heated at 90°C overnight. The mixture was quenched with satd. $NaHCO_3$, extracted with EtOAc (3x) and the combined organics were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (EtOAc/Hex) to afford 5-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-3-methyl-2-(methylthio)pyrimidin-4(3H)-one (0.52g, 67%). MS (ESI) m/z : 375.1 ($M+H^+$).

[0197] A mixture of 5-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-3-methyl-2-(methylthio)pyrimidin-4(3H)-one (0.52 g, 0.97 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.22 g, 1.07 mmol), and K_2CO_3 (0.40 g, 2.9 mmol) in 5:1 dioxane/water (6 mL) was sparged with Ar, treated with $Pd(PPh_3)_4$ (0.12 g, 0.10 mmol), sparged again with Ar and heated at 90°C overnight. The solids were removed via filtration, the filtrate treated with satd. $NaHCO_3$, extracted with EtOAc (3x) and the combined organics

were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford 3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylthio)pyrimidin-4(3H)-one (140 mg, 34%). MS (ESI) m/z : 421.1 ($\text{M}+\text{H}^+$).




Example C4: A solution of **Example B3** (0.698 g, 2.381 mmol) in dioxane (20 mL) was treated with **Example A1** (0.7 g, 2.4 mmol), a solution of K_2CO_3 (0.22 g, 1.6 mmol) in water (6 mL) and $\text{Pd}(\text{PPh}_3)_4$ (0.18 g, 0.16 mmol), sparged with Ar and heated at 90°C overnight. The mixture was cooled to RT, treated with water, extracted with EtOAc (2x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified by silica gel chromatography (EtOAc/Hex) to afford 5-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-N-isopropyl-4-methoxypyrimidin-2-amine (0.48 g, 55%). MS (ESI) m/z : 386.2 ($\text{M}+\text{H}^+$).



Example 1: A solution of **Example C1** (0.12 g, 0.26 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.070 g, 0.35 mmol) in dioxane (4 mL) was sparged with Ar, treated with a solution of K_2CO_3 (0.07 g, 0.51 mmol) in water (1 mL), $\text{Pd}(\text{PPh}_3)_4$ (0.03 g, 0.026 mmol) and heated at 90°C for 2 h. The mixture was cooled to RT, diluted with water, extracted with EtOAc (2x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified by column chromatography (MeOH/DCM) to afford N-ethyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine as a white solid (77 mg, 71%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.74 (s, 1 H), 8.36 (d, $J = 5.7$ Hz, 1 H), 8.26 (s, 1 H), 7.97 (d, $J = 0.7$ Hz, 1 H), 7.76 (d, $J = 8.5$ Hz, 1 H), 7.55 (d, $J = 8.6$ Hz, 1 H), 7.36 (br s, 1 H), 7.25 (d, $J =$

2.4 Hz, 1 H), 6.61 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.96 (s, 3 H), 3.84 (s, 3 H), 3.40-3.30 (m, 2 H), 2.37 (s, 3 H), 1.14 (br m, 3 H); MS (ESI) m/z : 418.2 ($M+H^+$).


[0198] A mixture of N-ethyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.29 g, 0.7 mmol) and 48% aq. HBr (0.32 mL, 2.78 mmol) in acetic acid (5 mL) was heated at 90°C for 6 h. The mixture was cooled to RT, diluted with water (60 mL), made basic with solid NaHCO_3 , extracted with 1:1 EtOAc/THF (3x) and the combined organics were washed with brine, dried over Na_2SO_4 and concentrated to dryness. The residue was stirred with MeCN for 1 h and the resulting solid was collected via filtration to afford 2-(ethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one as white solid (210 mg, 75%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.20 (br s, 1 H), 8.67 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.24-8.26 (m, 2 H), 7.96 (s, 1 H), 7.50 (d, $J = 8.6$ Hz, 1 H), 7.21 (d, $J = 2.4$ Hz, 1 H), 6.88 (br s, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.84 (s, 3 H), 3.34-3.32 (m, 2 H), 2.34 (s, 3 H), 1.12 (t, $J = 7.2$ Hz, 3 H); MS (ESI) m/z : 404.2 ($M+H^+$).



Example 2: A solution of **Example C2** (0.13 g, 0.309 mmol) in DCM (5 mL) was treated portion-wise with mCPBA (0.09 g, 0.37 mmol), stirred at RT overnight, treated with TEA (0.5 mL) and N,N-dimethylamine HCl salt (500 mg) and stirred at RT for 2 h. The mixture was treated with satd. NaHCO_3 , extracted with DCM (2x) and the combined organics were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain 4-methoxy-N,N-dimethyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (60 mg, 47%). MS (ESI) m/z : 418.2 ($M+H^+$).


[0199] A solution of 4-methoxy-N,N-dimethyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.060 g, 0.144 mmol) in acetic acid (5 mL) was treated with HBr (0.065 mL, 0.575 mmol), heated at 90°C for 6 h, cooled to RT and quenched with ice water. The solution was treated with NaHCO_3 and NaCl, extracted with 1:1 THF/EtOAc (3x) and the combined organics were dried over Na_2SO_4 and concentrated to dryness. The material was treated with MeCN (1 mL), allowed to stand at RT and the

resulting solid was collected via filtration to afford 2-(dimethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (43 mg, 71%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.23 (s, 1 H), 8.73 (s, 1 H), 8.36 (d, *J* = 5.7 Hz, 1 H), 8.30 (m, 1H), 8.26 (s, 1 H), 7.97 (s, 1 H), 7.51 (m, 1H), 7.23 (d, *J* = 2.4 Hz, 1 H), 6.62 (br s, 1 H), 3.85 (s, 3 H), 3.12 (s, 6 H), 2.35 (s, 3 H); MS (ESI) *m/z*: 404.2 (M+H⁺).




Example 3: A solution of **Example C2** (0.13 g, 0.309 mmol) in DCM (5 mL) was treated portion-wise with mCPBA (0.09 g, 0.37 mmol), stirred at RT overnight, treated with isopropyl amine (0.5 mL) and stirred at RT overnight. The mixture was treated with satd. NaHCO₃, extracted with DCM (2x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain N-isopropyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (63 mg, 47%). MS (ESI) *m/z*: 432.2 (M+H⁺).

[0200] A solution of N-isopropyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.063 g, 0.14 mmol) in acetic acid (5 mL) was treated with HBr (0.066 mL, 0.58 mmol), heated at 90°C for 4 h, cooled to RT and quenched with ice water. The solution was treated with NaHCO₃ and NaCl, extracted with 1:1 THF/EtOAc (3x) and the combined organics were dried over Na₂SO₄ and concentrated to dryness. The material was treated with MeCN (1 mL), allowed to stand at RT and the resulting solid was collected via filtration to afford 2-(isopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (25 mg, 38%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.8 (br s, 1 H), 8.68 (s, 1 H), 8.36 (d, *J* = 5.7 Hz, 1 H), 8.27 (s, 1 H), 8.26 (s, 1 H), 7.96 (s, 1 H), 7.51 (d, *J* = 8.6 Hz, 1 H), 7.22 (d, *J* = 2.4 Hz, 1 H), 6.67 (br s, 1 H), 6.61 (d, *J* = 5.6 Hz, 1 H), 4.07 (m, 1 H), 3.85 (s, 3 H), 2.34 (s, 3 H), 1.17 (d, *J* = 6.5 Hz, 6 H); MS (ESI) *m/z*: 418.2 (M+H⁺).



Example 4: A solution of **Example C1** (0.15 g, 0.4 mmol) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.13 g, 0.57 mmol) in dioxane (4 mL) was sparged with Ar, treated with a solution of K_2CO_3 (0.11 g, 0.8 mmol) in water (1 mL) and heated at 90°C for 2 h. The mixture was cooled to RT, diluted with water, extracted with EtOAc (3x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford N-ethyl-4-methoxy-5-(6-methyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine as an orange foam (0.106 g, 61%). ^1H NMR (400 MHz, $DMSO-d_6$): δ 9.11 (d, J = 2.4 Hz, 1 H), 8.74 (s, 1 H), 8.54 (d, J = 5.7 Hz, 1 H), 8.29 (dd, J = 8.1, 2.4 Hz, 1 H), 7.77 (d, J = 8.6 Hz, 1 H), 7.65 (d, J = 2.4 Hz, 1 H), 7.59 (d, J = 8.6 Hz, 1 H), 7.34 (d, J = 8.2 Hz, 1 H), 7.02 (d, J = 1.9 Hz, 1 H), 6.79 (dd, J = 5.7, 2.4 Hz, 1 H), 3.96 (s, 3 H), 3.36-3.34 (m, 2 H), 2.51 (s, 3 H), 2.38 (s, 3 H), 1.15 (s, 3 H); MS (ESI) m/z : 429.2 ($M+H^+$).


[0201] Using the procedure of **Example 1**, N-ethyl-4-methoxy-5-(6-methyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.13 g, 0.3 mmol) and 48% HBr (0.66 mL, 12 mmol) were combined to afford 2-(ethylamino)-5-(6-methyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one as a white solid (0.09 g, 73%). ^1H NMR (400 MHz, $DMSO-d_6$): δ 11.08 (s, 1 H), 9.10 (s, 1 H), 8.68 (s, 1 H), 8.53 (d, J = 5.7 Hz, 1 H), 8.28 (d, J = 8.3 Hz, 2 H), 7.62 (s, 1 H), 7.54 (d, J = 8.7 Hz, 1 H), 7.34 (d, J = 8.2 Hz, 1 H), 6.82 (br s, 1 H), 6.78 (d, J = 5.7 Hz, 1 H), 3.35-3.32 (m, 2 H), 2.50 (s, 3 H), 2.35 (s, 3 H), 1.12 (t, J = 7.2 Hz, 3 H); MS (ESI) m/z : 415.2 ($M+H^+$).



Example 5: A mixture of Me₄tBuXPhos (0.018 g, 0.043 mmol) and $Pd_2(dba)_3$ (0.020 g, 0.022 mmol) in dioxane (1 mL) was sparged with Ar, heated at 100°C for a few minutes, treated with **Example C1** (0.16 g, 0.43 mmol), 4-methyl-1H-imidazole (0.1 g, 1.3 mmol) and

K₃PO₄ (0.18 g, 0.86 mmol) and heated at 100°C for 20 h. The mixture was cooled to RT, diluted with EtOAc, the solids removed via filtration through diatomaceous earth and washed with EtOAc. The filtrate was washed with water, then brine, dried over Na₂SO₄, concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford N-ethyl-4-methoxy-5-(6-methyl-5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine as a white solid (0.12 g, 67%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.75 (s, 1 H), 8.40 (d, *J* = 1.4 Hz, 1 H), 8.32 (d, *J* = 5.8 Hz, 1 H), 7.77 (d, *J* = 8.7 Hz, 1 H), 7.65 (s, 1 H), 7.59 (d, *J* = 8.6 Hz, 1 H), 7.49 (br s, 1 H), 7.42 (d, *J* = 2.2 Hz, 1 H), 6.74 (dd, *J* = 5.8, 2.2 Hz, 1 H), 3.96 (s, 3 H), 3.36-3.34 (m, 2 H), 2.37 (s, 3 H), 2.13 (s, 3 H), 1.14 (s, 3 H); MS (ESI) *m/z*: 418.2 (M+H⁺).


[0202] Using the procedure of **Example 1**, N-ethyl-4-methoxy-5-(6-methyl-5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.12 g, 0.29 mmol) and 48% HBr (0.63 mL, 11.5 mmol) were combined to afford 2-(ethylamino)-5-(6-methyl-5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one as a white solid (0.06 g, 51%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.60 (br s, 1 H), 8.68 (s, 1 H), 8.40 (d, *J* = 1.3 Hz, 1 H), 8.31-8.30 (m, 2 H), 7.64 (s, 1 H), 7.54 (d, *J* = 8.6 Hz, 1 H), 7.39 (d, *J* = 2.2 Hz, 1 H), 6.93 (br s, 1 H), 6.73 (dd, *J* = 5.8, 2.2 Hz, 1 H), 3.35-3.33 (m, 2 H), 2.35 (s, 3 H), 2.13 (s, 3 H), 1.12 (t, *J* = 7.1 Hz, 3 H); MS (ESI) *m/z*: 404.2 (M+H⁺).



Example 6: A solution of **Example C2** (0.15 g, 0.36 mmol) in DCM (5 mL) was treated portion-wise with mCPBA (0.11 g, 0.43 mmol), stirred at RT overnight, treated with 2-methoxyethanamine (0.5 mL) and stirred at RT for 4 h. The mixture was treated with satd. NaHCO₃, extracted with DCM (3x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain 4-methoxy-N-(2-methoxyethyl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (100 mg, 63%). MS (ESI) *m/z*: 448.2 (M+H⁺).


[0203] A solution of 4-methoxy-N-(2-methoxyethyl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.10 g, 0.22 mmol) in acetic acid (5 mL) was treated with HBr (0.10 mL, 0.90 mmol), heated at 90°C for 4 h, cooled to

RT and quenched with ice water. The solution was treated with NaHCO_3 and NaCl , extracted with EtOAc (3x) and the combined organics were dried over Na_2SO_4 and concentrated to dryness. The material was treated with MeCN (3 mL) and the resulting solid was collected via filtration to afford 2-((2-methoxyethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (65 mg, 61%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.02 (br s, 1 H), 8.67 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.29-8.23 (m, 2 H), 7.96 (d, $J = 0.7$ Hz, 1 H), 7.50 (d, $J = 8.6$ Hz, 1 H), 7.22 (d, $J = 2.4$ Hz, 1 H), 6.85 (br s, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.84 (s, 3 H), 3.53-3.44 (m, 4 H), 3.28 (s, 3 H), 2.34 (s, 3 H); MS (ESI) m/z : 434.2 ($\text{M}+\text{H}^+$).



Example 7: A solution of **Example C2** (0.15 g, 0.357 mmol) in DCM (5 mL) was treated portion-wise with mCPBA (0.11 g, 0.43 mmol), stirred at RT overnight, treated with methylamine (2.0M in THF, 3.6 mL, 7.2 mmol) and stirred at RT for 4 h. The mixture was treated with satd. NaHCO_3 , extracted with DCM (3x) and the combined organics were dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain 4-methoxy-N-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (100 mg, 70%). MS (ESI) m/z : 404.2 ($\text{M}+\text{H}^+$).


[0204] A solution of 4-methoxy-N-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.10 g, 0.25 mmol) in acetic acid (5 mL) was treated with HBr (0.12 mL, 1.0 mmol) and heated at 90°C for 4 h. The mixture was cooled to RT, quenched with ice water, treated with NaHCO_3 and NaCl , and extracted with EtOAc (3x). The combined organics were dried over Na_2SO_4 , concentrated to dryness, the resulting material treated with MeCN (3 mL) and the solid was collected via filtration to afford 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylamino)pyrimidin-4(3H)-one (52 mg, 53%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.26 (s, 1 H), 8.70 (s, 1 H), 8.36 (d, $J = 5.7$ Hz, 1 H), 8.28 (m, 1 H), 8.26 (s, 1 H), 7.97 (s, 1 H), 7.51 (d, $J = 8.6$ Hz, 1 H), 7.22 (d, $J = 2.4$ Hz, 1 H), 6.70 (br s, 1 H), 6.61 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.85 (s, 3 H), 2.85 (d, $J = 4.7$ Hz, 3 H), 2.35 (s, 3 H); MS (ESI) m/z : 390.2 ($\text{M}+\text{H}^+$).



Example 8: A mixture of **Example B1** (0.20 g, 0.51 mmol), **Example A5** (0.17 g, 0.51 mmol) and K_2CO_3 (0.21 g, 1.52 mmol) in dioxane (6 mL) and water (1.5 mL) was sparged with Ar, treated with $Pd(PPh_3)_4$ (0.06 g, 0.051 mmol), sparged again with Ar and heated at $90^\circ C$ for 7 h. The mixture was cooled to RT, treated with satd. $NaHCO_3$, extracted with EtOAc (3x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (EtOAc/Hex) to obtain 5-((5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-N-ethyl-4-methoxypyrimidin-2-amine (90 mg, 50%). MS (ESI) m/z : 358.1 ($M+H^+$).


[0205] A mixture of 5-((5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-N-ethyl-4-methoxypyrimidin-2-amine (0.090 g, 0.25 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.060 g, 0.28 mmol), and K_2CO_3 (0.10 g, 0.76 mmol) in 5:1 dioxane/water (6 mL) was sparged with Ar, treated with $Pd(PPh_3)_4$ (0.03 g, 0.025 mmol), sparged again with Ar and heated at $90^\circ C$ for 7 h. The mixture was cooled to RT, quenched with satd. $NaHCO_3$, extracted with EtOAc (3x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain N-ethyl-4-methoxy-5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (80 mg, 79%). MS (ESI) m/z : 404.2 ($M+H^+$).

[0206] Using the procedure of **Example 7**, N-ethyl-4-methoxy-5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.080 g, 0.20 mmol) was combined with acetic acid (3 mL) and HBr (0.090 mL, 0.79 mmol) to afford 2-(ethylamino)-5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (40 mg, 51%). ^1H NMR (400 MHz, $DMSO-d_6$): δ 11.12 (s, 1 H), 8.66 (s, 1 H), 8.43 (m, 2 H), 8.38 (d, $J = 5.7$ Hz, 1 H), 8.26 (s, 1 H), 7.97 (d, $J = 0.7$ Hz, 1 H), 7.62 (dd, $J = 8.8, 2.9$ Hz, 1 H), 7.28 (d, $J = 2.4$ Hz, 1 H), 6.38 (br s, 1 H), 6.72 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.85 (s, 3 H), 3.35 (m, 2 H), 1.12 (t, $J = 7.2$ Hz, 3 H); MS (ESI) m/z : 390.2 ($M+H^+$).




Example 9: A solution of **Example C2** (0.15 g, 0.36 mmol) in DCM (5 mL) was treated with mCPBA (0.11 g, 0.43 mmol), stirred at RT for 2 h, treated with pyrrolidine (0.5 mL) and stirred at RT overnight. The mixture was treated with satd. NaHCO₃, extracted with DCM (3x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to obtain 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidine (100 mg, 63%). MS (ESI) *m/z*: 444.2 (M+H⁺).

[0207] A solution of 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidine (0.1 g, 0.22 mmol) in acetic acid (3 mL) was treated with HBr (0.1 mL, 0.90 mmol) and heated at 90°C for 6.5 h. The mixture was cooled to RT, quenched with ice water, neutralized with NaHCO₃ to pH=8 and extracted with EtOAc (3x). The combined organics were dried over Na₂SO₄, concentrated to dryness, the resulting material treated with MeCN and the solid was collected via filtration to afford 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one (89 mg, 91%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.21 (s, 1 H), 8.73 (s, 1 H), 8.36 (d, *J* = 5.7 Hz, 1 H), 8.31 (m, 1 H), 8.26 (s, 1 H), 7.97 (d, *J* = 0.7 Hz, 1 H), 7.52 (m, 1 H), 7.22 (d, *J* = 2.4 Hz, 1 H), 6.61 (d, *J* = 5.6 Hz, 1 H), 3.85 (s, 3 H), 3.50 (m, 4 H), 2.35 (s, 3 H), 1.91 (m, 4 H); MS (ESI) *m/z*: 430.2 (M+H⁺).



Example 10: A mixture of **Example C3** (0.14 g, 0.33 mmol) and isopropyl amine (3 mL, 35.0 mmol) was heated at 100°C for 2 days in a sealed tube. The mixture was cooled to RT, the solid removed via filtration and the filtrate concentrated to dryness and purified via silica gel chromatography to obtain 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (88 mg, 59%). ¹H NMR


(400 MHz, DMSO-*d*₆): δ 8.68 (s, 1 H), 8.36 (d, *J* = 5.7 Hz, 1 H), 8.28 (d, *J* = 8.7 Hz, 1 H), 8.25 (s, 1 H), 7.96 (d, *J* = 0.7 Hz, 1 H), 7.52 (d, *J* = 8.6 Hz, 1 H), 7.23 (d, *J* = 2.4 Hz, 1 H), 7.05 (d, *J* = 7.6 Hz, 1 H), 6.60 (dd, *J* = 5.7, 2.4 Hz, 1 H), 4.33 (m, 1 H), 3.85 (s, 3 H), 3.37 (s, 3 H), 2.35 (s, 3 H), 1.23 (d, *J* = 6.6 Hz, 6 H); MS (ESI) *m/z*: 432.2 (M+H⁺).



Example 11: A suspension of PdCl₂(dppf)·CH₂Cl₂ (0.048 g, 0.059 mmol), KOAc (0.086 g, 0.879 mmol), bis(pinacolato)diboron (0.186 g, 0.732 mmol), and 5-bromo-N-isopropyl-4-methoxypyrimidin-2-amine (0.144 g, 0.586 mmol) in dioxane (6 mL) was sparged with Ar and heated at 90°C for 20 h. The mixture was cooled to RT, treated with additional PdCl₂(dppf)·CH₂Cl₂ (0.048 g, 0.059 mmol), KOAc (0.086 g, 0.879 mmol) and bis(pinacolato)diboron (0.186 g, 0.732 mmol), sparged with Ar and heated at 100°C for 20 h. The mixture was cooled to RT, treated with Pd(PPh₃)₄ (0.034 g, 0.029 mmol), K₂CO₃ (0.121 g, 0.879 mmol), **Example A6** (0.104 g, 0.293 mmol) and water (1.5 mL), sparged with Ar, heated at 85°C for 18 h, then cooled to RT. The mixture was treated with satd. NaHCO₃, extracted with EtOAc (4x) and the combined organics were washed with brine, dried over Na₂SO₄, concentrated to dryness and purified by silica gel chromatography (EtOAc/DCM) to afford 4-((6-(2-(isopropylamino)-4-methoxypyrimidin-5-yl)pyridin-3-yl)oxy)-N-methylpicolinamide (72 mg, 62%). MS (ESI) *m/z*: 395.2 (M+H⁺).


[0208] A solution of 4-((6-(2-(isopropylamino)-4-methoxypyrimidin-5-yl)pyridin-3-yl)oxy)-N-methylpicolinamide (0.072 g, 0.183 mmol) in DCE (10 mL) was treated with iodotrimethylsilane (0.497 mL, 3.65 mmol), heated at 50°C for 20 h, treated with additional iodotrimethylsilane (0.25 mL, 1.84 mmol) and heated at 60°C for 20 h. The mixture was cooled to RT, treated with DCM/THF (5:1), washed with satd. NaHCO₃, 10% sodium bisulfite, then brine. The combined aqueous washes were back-extracted with DCM/THF (5:1) (1x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified by preparatory TLC (EtOAc) to afford 4-((6-(2-(isopropylamino)-6-oxo-1,6-dihydropyrimidin-5-yl)pyridin-3-yl)oxy)-N-methylpicolinamide (16 mg, 23%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.89 (br s, 1 H), 8.79 (d, *J* = 5.2 Hz, 1 H), 8.66 (s, 1 H), 8.52 (d, *J* = 5.6 Hz, 1 H), 8.47 (d, *J* = 2.9 Hz, 1 H), 8.44 (d, *J* = 8.8 Hz, 1 H), 7.67 (dd, *J* = 8.8, 2.9 Hz, 1

H), 7.42 (d, $J = 2.6$ Hz, 1 H), 7.21 (dd, $J = 5.6, 2.6$ Hz, 1 H), 6.74 (br s, 1 H), 4.08 (m, 1 H), 2.77 (d, $J = 4.8$ Hz, 3 H), 1.16 (d, $J = 6.5$ Hz, 6 H); MS (ESI) m/z : 381.2 ($M+H^+$).



Example 12: Using the procedure of **Example 6**, **Example C2** (0.15 g, 0.357 mmol), mCPBA (0.106 g, 0.428 mmol) and morpholine (0.5 mL, 5.78 mmol) were combined to afford 4-(4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-yl)morpholine (127 mg, 77%). MS (ESI) m/z : 460.2 ($M+H^+$).


[0209] Using the procedure of **Example 6**, 4-(4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-yl)morpholine (0.127 g, 0.276 mmol) and HBr (0.126 mL, 1.106 mmol) were combined in acetic acid (3 mL) to afford 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-morpholinopyrimidin-4(3H)-one (75 mg, 59%). ^1H NMR (400 MHz, DMSO- d_6): δ 11.57 (br s, 1 H), 8.77 (s, 1 H), 8.36 (d, $J = 5.7$ Hz, 1 H), 8.27-8.22 (m, 2 H), 7.97 (s, 1 H), 7.59 (m, 1 H), 7.24 (d, $J = 2.4$ Hz, 1 H), 6.63 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.84 (s, 3 H), 3.68-3.63 (m, 8 H), 2.36 (s, 3 H); MS (ESI) m/z : 446.2 ($M+H^+$).



Example 13: Using the procedure of **Example 6**, **Example C2** (0.15 g, 0.357 mmol), mCPBA (0.106 g, 0.428 mmol) and piperidine (0.6 mL, 6.07 mmol) were combined to afford 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(piperidin-1-yl)pyrimidine (134 mg, 82%). MS (ESI) m/z : 458.2 ($M+H^+$).


[0210] Using the procedure of **Example 6**, 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(piperidin-1-yl)pyrimidine (0.134 g, 0.293 mmol) and HBr (0.133 mL, 1.172 mmol) were combined in acetic acid (3 mL) to afford 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-

(piperidin-1-yl)pyrimidine (103 mg, 79%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.33 (br s, 1 H), 8.71 (br s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.31-8.18 (m, 2 H), 7.96 (s, 1 H), 7.53 (br s, 1 H), 7.23 (d, $J = 2.4$ Hz, 1 H), 6.61 (m, 1 H), 3.84 (s, 3 H), 3.68 (m, 4 H), 2.35 (s, 3 H), 1.61 (m, 2 H), 1.53 (m, 4 H); MS (ESI) m/z : 444.2 ($\text{M}+\text{H}^+$).




Example 14: Using the procedure of **Example 6**, **Example C2** (0.100 g, 0.238 mmol), mCPBA (0.070 g, 0.285 mmol) and cyclopropylamine (0.300 mL, 4.33 mmol) were combined to afford N-cyclopropyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (82 mg, 80%). MS (ESI) m/z : 430.2 ($\text{M}+\text{H}^+$).

[0211] A solution of N-cyclopropyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.082 g, 0.191 mmol) in acetic acid (2 mL) was treated with HBr (0.087 mL, 0.764 mmol) and heated at 90°C for 4 h. The mixture was cooled to RT, treated with ice, neutralized with satd. NaHCO_3 and extracted with EtOAc (3x). The combined organics were washed with brine, dried over MgSO_4 , concentrated to dryness, treated with MeCN, sonicated, heated to near-boiling and allowed to stand at RT overnight. The resulting solid was collected via filtration. The combined aqueous washes were filtered, the solid washed with water, dried and combined with the above-isolated solid to afford 2-(cyclopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (35 mg, 44%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.09 (br s, 1 H), 8.68 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.28 (m, 1 H), 8.25 (s, 1 H), 7.96 (d, $J = 0.8$ Hz, 1 H), 7.66 (br s, 1 H), 7.52 (d, $J = 8.6$ Hz, 1 H), 7.22 (d, $J = 2.4$ Hz, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.84 (s, 3 H), 2.73-2.68 (m, 1 H), 2.34 (s, 3 H), 0.75 (m, 2 H), 0.55-0.53 (m, 2 H); MS (ESI) m/z : 416.2 ($\text{M}+\text{H}^+$).




Example 15: Using the procedure of **Example 6**, **Example C2** (0.100 g, 0.238 mmol), mCPBA (0.070 g, 0.285 mmol) and cyclopentylamine (0.400 mL, 4.04 mmol) were combined to afford N-cyclopentyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (85 mg, 78%). MS (ESI) m/z : 458.2 ($M+H^+$).


[0212] Using the procedure of **Example 6**, N-cyclopentyl-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.085 g, 0.186 mmol) and HBr (0.085 mL, 0.743 mmol) were combined in acetic acid (2 mL) to afford 2-(cyclopentylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (58 mg, 70%). ^1H NMR (400 MHz, DMSO- d_6): δ 10.78 (br s, 1 H), 8.67 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.29-8.23 (m, 2 H), 7.96 (s, 1 H), 7.50 (d, $J = 8.6$ Hz, 1 H), 7.22 (d, $J = 2.4$ Hz, 1 H), 6.94 (br s, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 4.21-4.18 (m, 1 H), 3.84 (s, 3 H), 2.34 (s, 3 H), 1.92-1.89 (m, 2 H), 1.68-1.64 (m, 2 H), 1.58-1.54 (m, 2 H), 1.49-1.40 (m, 2 H); MS (ESI) m/z : 444.2 ($M+H^+$).



Example 16: A solution of **Example C3** (0.087 g, 0.207 mmol) in pyrrolidine (1.75 mL, 21.31 mmol) was heated at 100°C in a sealed vessel overnight, cooled to RT, concentrated to dryness and purified via silica gel chromatography (EtOAc, MeOH/DCM). The material was treated with MeCN, sonicated and the resulting solid collected via filtration and dried to afford 3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one (62 mg, 67%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.65 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.30 (d, $J = 8.6$ Hz, 1 H), 8.25 (s, 1 H), 7.96 (s, 1 H), 7.54 (d, $J = 8.6$ Hz, 1 H), 7.24 (d, $J = 2.4$ Hz, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.84 (s, 3 H), 3.58 (m, 4 H), 3.45 (s, 3 H), 2.35 (s, 3 H), 1.87 (m, 4 H); MS (ESI) m/z : 444.2 ($M+H^+$).




Example 17: Using the procedure of **Example 16**, **Example C3** (0.087 g, 0.207 mmol) and cyclopropylamine (1.5 mL, 21.65 mmol) were combined to afford 2-(cyclopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (49 mg, 55%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 8.70 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.29-8.25 (m, 2 H), 7.96 (s, 1 H), 7.52 (d, $J = 8.6$ Hz, 1 H), 7.48 (d, $J = 3.1$ Hz, 1 H), 7.23 (d, $J = 2.4$ Hz, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 3.84 (s, 3 H), 3.33 (s, 3 H), 2.88-2.87 (m, 1 H), 2.35 (s, 3 H), 0.77-0.71 (m, 2 H), 0.65-0.61 (m, 2 H); MS (ESI) m/z : 430.2 ($\text{M}+\text{H}^+$).



Example 18: A solution of **Example B3** (0.13 g, 0.44 mmol) in dioxane (4 mL) was treated with **Example A3** (0.09 g, 0.26 mmol), $\text{Pd(PPh}_3)_4$ (0.03 g, 0.026 mmol), a solution of K_2CO_3 (0.036 g, 0.26 mmol) in water (1 mL) and heated at 90°C overnight. The mixture was cooled to RT, treated with water, extracted with EtOAc (2x) and the combined organics were washed with brine, dried over Na_2SO_4 , concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford N-isopropyl-4-methoxy-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (55 mg, 49%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 8.69 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 2 H), 8.26 (s, 1 H), 7.97 (s, 1 H), 7.84 (s, 1 H), 7.25 (d, $J = 2.4$ Hz, 1 H), 6.59 (dd, $J = 5.7$ Hz, 2.5 Hz, 1 H), 4.15-4.12 (m, 1 H), 3.97 (s, 3 H), 3.84 (s, 3 H), 2.17 (s, 3 H), 1.175 (d, $J = 6.4$ Hz, 6 H); MS (ESI) m/z : 432.2 ($\text{M}+\text{H}^+$).


[0213] Using the procedure of **Example 3**, N-isopropyl-4-methoxy-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.053 g, 0.12 mmol) and HBr (0.2 mL) were combined in acetic acid (3 mL) to afford 2-(isopropylamino)-

5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (0.03 g, 59%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.86 (s, 1 H), 8.65 (s, 1 H), 8.34 (m, 2 H), 8.30 (s, 1 H), 8.25 (s, 1 H), 7.96 (s, 1 H), 7.21 (d, *J* = 2.4 Hz, 1 H), 6.63 (br s, 1 H), 6.58 (dd, *J* = 5.7, 2.4 Hz, 1 H), 4.09-4.07 (m, 1 H), 3.84 (s, 3 H), 2.14 (s, 3 H), 1.16 (d, *J* = 6.5 Hz, 6 H); MS (ESI) *m/z*: 418.2 (M+H⁺).



Example 19: A solution of **Example C4** in dioxane (3 mL) was treated with acetamide (0.06 g, 1.0 mmol), Cs₂CO₃ (0.11 g, 0.34 mmol), X-Phos (0.03 g, 0.077 mmol) and Pd₂(dba)₃ (0.03 g, 0.034 mmol) and heated at 80°C overnight. The mixture was diluted with EtOAc, the solids removed via filtration through diatomaceous earth, washed with EtOAc and the filtrate was washed with water, then brine, dried over Na₂SO₄, concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford N-(4-((6-(2-(isopropylamino)-4-methoxypyrimidin-5-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)acetamide (60 mg, 36%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.56 (s, 1 H), 8.73 (s, 1 H), 8.18 (d, *J* = 5.7 Hz, 1 H), 7.76 (d, *J* = 8.4 Hz, 1 H), 7.62 (s, 1 H), 7.55 (d, *J* = 8.6 Hz, 1 H), 7.44-7.18 (br m, 1 H), 6.63 (dd, *J* = 5.7, 2.4 Hz, 1 H), 4.10 (m, 1 H), 3.95 (s, 3 H), 2.33 (s, 3 H), 2.02 (s, 3 H), 1.17 (d, *J* = 6.4 Hz, 6 H); MS (ESI) *m/z*: 409.2 (M+H⁺).

[0214] A solution of N-(4-((6-(2-(isopropylamino)-4-methoxypyrimidin-5-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)acetamide (0.05 g, 0.12 mmol) in DCE (3 mL) was treated with TMS-I (0.5 mL, 3.67 mmol) and heated at 50°C for 4 h. The mixture was diluted with 10% Na₂S₂O₃ and 1:1 THF/EtOAc, stirred for few minutes, the layers separated and the aqueous layer extracted with EtOAc (1x). The combined organics were washed with brine, dried over Na₂SO₄, concentrated to dryness and purified by silica gel chromatography (MeOH/EtOAc) to afford N-(4-((6-(2-(isopropylamino)-4-methoxypyrimidin-5-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)acetamide (0.018 g, 37%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.79 (s, 1 H), 10.51 (s, 1 H), 8.61 (s, 1 H), 8.20 (d, *J* = 8.6 Hz, 1 H), 8.12 (d, *J* = 5.7 Hz, 1 H), 7.54 (s, 1 H), 7.47-7.46 (m 1 H), 6.64 (br s, 1 H), 6.58 (dd, *J* = 5.8, 2.4 Hz, 1 H), 4.03-3.99 (m, 1 H), 2.26 (s, 3 H), 1.97 (s, 3 H), 1.11 (d, *J* = 6.5 Hz, 6 H); MS (ESI) *m/z*: 395.2 (M+H⁺).




Example 20: A suspension of **Example A4** (0.25 g, 0.64 mmol), **Example B2** (0.22 g, 0.78 mmol), and K_2CO_3 (0.27 g, 2.0 mmol) in dioxane (5 mL) and water (1 mL) was sparged with Ar, treated with $Pd(PPh_3)_4$ (0.070 g, 0.061 mmol) and heated at 90°C for 16 h. The mixture was cooled to RT, treated with satd. $NaHCO_3$, extracted with EtOAc (4x) and the combined organics were dried over $MgSO_4$, concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford 4-methoxy-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylthio)pyrimidine (0.28 g, 99 %). ^1H NMR (400 MHz, $DMSO-d_6$): δ 8.89 (s, 1 H), 8.47 (s, 1 H), 8.37 (d, $J = 5.7$ Hz, 1 H), 8.27 (s, 1 H), 7.98 (d, $J = 5.7$ Hz, 2 H), 7.28 (d, $J = 2.4$ Hz, 1 H), 6.63 (dd, $J = 5.7, 2.5$ Hz, 1 H), 4.07 (s, 3 H), 3.85 (s, 3 H), 2.58 (s, 3 H), 2.22 (s, 3 H); MS (ESI) m/z : 421.1 ($M+H^+$).

[0215] A solution of 4-methoxy-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylthio)pyrimidine (0.28 g, 0.67 mmol) in DCM (10 mL) was treated with mCPBA (0.20 g, 0.80 mmol), stirred at RT for 3 h, treated with pyrrolidine (0.50 mL, 6.1 mmol) and stirred at RT overnight. The mixture was treated with satd. $NaHCO_3$, extracted with DCM (3x) and the combined organics were dried over $MgSO_4$, concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford 4-methoxy-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidine (0.19 g, 64%). ^1H NMR (400 MHz, $DMSO-d_6$): δ 8.76 (s, 1 H), 8.37 (s, 1 H), 8.35 (d, $J = 5.7$ Hz, 1 H), 8.27 (s, 1 H), 7.97 (s, 1 H), 7.85 (s, 1 H), 7.25 (d, $J = 2.4$ Hz, 1 H), 6.60 (dd, $J = 5.7, 2.5$ Hz, 1 H), 4.00 (s, 3 H), 3.84 (s, 3 H), 3.55 (s, 5 H), 2.18 (s, 3 H), 1.93-1.92 (m, 4 H); MS (ESI) m/z : 444.2 ($M+H^+$).

[0216] A solution of 4-methoxy-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidine (0.19 g, 0.43 mmol) in acetic acid (2.5 mL) was treated with HBr (48%, 0.10 mL, 1.8 mmol) and heated at 90°C for 16 h. The mixture was poured onto ice (10 g), neutralized with satd. $NaHCO_3$, and the resulting solid was collected by filtration, washed with water and MeCN and dried to afford 5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-


4(3H)-one (0.11 g, 58%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.22 (bs, 1 H), 8.68 (s, 1 H), 8.38 (s, 1 H), 8.34 (d, $J = 5.7$ Hz, 1 H), 8.30 (d, $J = 1.3$ Hz, 1 H), 8.26 (s, 1 H), 7.96 (s, 1 H), 7.22 (d, $J = 2.4$ Hz, 1 H), 6.60-6.58 (m, 1 H), 3.84 (s, 3 H), 3.50 (bs, 4 H), 2.15 (s, 3 H), 1.91 (bs, 4 H); MS (ESI) m/z : 430.2 ($\text{M}+\text{H}^+$).



Example 21: Example C4 (0.30 g, 0.778 mmol), 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.19 g, 0.85 mmol), and potassium carbonate (0.32 g, 2.33 mmol) were combined in the mixture of dioxane: H_2 (4:1, 10 mL). The mixture was sparge with Ar and then tetrakis(triphenylphosphine)palladium(0) (0.090 g, 0.078 mmol) was added. The mixture was sparge with Ar again and heated at 90 °C overnight. The mixture was quenched with NaHCO_3 and extracted with EtOAc (3x). The organic was dried over Na_2SO_4 , filtered and concentrated to obtain the crude. The crude was purified via silica gel chromatography (EtOAc/hexane) to obtain 5-(5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-methylpyridin-2-yl)-N-isopropyl-4-methoxypyrimidin-2-amine (0.25 g, 72.2% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.75 (s, 1 H), 8.37 (d, $J = 5.7$ Hz, 1 H), 8.32 (s, 1 H), 7.99 (s, 1 H), 7.77 (m, 1 H), 7.56 (d, $J = 8.6$ Hz, 1 H), 7.27 (d, $J = 2.4$ Hz, 1 H), 6.61 (dd, $J = 5.7, 2.4$ Hz, 1 H), 4.14 (q, $J = 7.3$ Hz, 2 H), 4.01 (s, 1 H), 3.95 (m, 3 H), 2.37 (s, 3 H), 1.38 (t, $J = 7.3$ Hz, 3 H), 1.18 (d, $J = 6.5$ Hz, 6 H); MS (ESI) m/z : 446.3 ($\text{M}+\text{H}^+$).


[0217] 5-(5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-methylpyridin-2-yl)-N-isopropyl-4-methoxypyrimidin-2-amine (0.25 g, 0.56 mmol) was dissolved in AcOH (5 mL) and 48% hydrobromic acid (0.25 mL, 2.24 mmol) was added. The mixture was heated at 90 °C for 5 hours. The mixture was evaporated under high vacuum. The residue was treated with NaHCO_3 solution and the solution was extracted with EtOAc (3x). The organic was dried over Na_2SO_4 , filtered, and concentrated. The residue was treated with hot MeCN. The solid was filtered, and dried under vacuum to obtain 5-(5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-methylpyridin-2-yl)-2-(isopropylamino)pyrimidin-4(3H)-one (185 mg, 73.1% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.81 (s, 1 H), 8.68 (s, 1 H), 8.36 (d, $J = 5.7$ Hz, 1 H), 8.31 (s, 1 H), 8.26 (d, $J = 8.6$ Hz, 1 H), 7.98 (s, 1 H), 7.51 (d, $J = 8.6$ Hz, 1 H), 7.24 (d, $J = 2.4$ Hz, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 4.14 (q, $J = 7.3$ Hz, 2 H), 4.07 (m, 1

H), 2.34 (s, 3 H), 1.37 (t, $J = 7.3$ Hz, 3 H), 1.17 (d, $J = 6.5$ Hz, 6 H); MS (ESI) m/z : 432.2 ($M+H^+$).




Example 22: Example C2 (0.15 g, 0.36 mmol) was dissolved in DCM (5 mL) and then mCPBA (0.11 g, 0.43 mmol) was added portion wise. The mixture was stirred at RT for 3 hours. (S)-(+)-1-methoxy-2-propylamine (0.45 mL) was added and the mixture was stirred at RT for 2 days. The mixture was quenched with NaHCO_3 solution and the solution was extracted with DCM (2x). The organic was dried over Na_2SO_4 , filtered and concentrated to obtain the crude. The material was purified via silica gel chromatography (MeOH/DCM) to obtain (R)-4-methoxy-N-(1-methoxypropan-2-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (98 mg, 59.5% yield). MS (ESI) m/z : 462.2 ($M+H^+$).

[0218] (R)-4-methoxy-N-(1-methoxypropan-2-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (98 mg, 0.21 mmol) was dissolved in AcOH (3 mL) and then hydrobromic acid (0.1 mL, 0.85 mmol) was added. The mixture was heated at 90°C for 3.5 hours. The mixture was concentrated and the residue was treated with NaHCO_3 solution. The solution was extracted with EtOAc (3x). The organic was washed with NaHCO_3 , dried over Na_2SO_4 , filtered and concentrated to obtain the crude. The crude was treated with hot MeCN and kept at RT. The solid was filtered and washed with MeCN and dried under vacuum to obtain (R)-2-((1-methoxypropan-2-yl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (67 mg, 59.2% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.85 (s, 1 H), 8.67 (s, 1 H), 8.36 (d, $J = 5.7$ Hz, 1 H), 8.25 (m, 2 H), 7.97 (s, 1 H), 7.51 (d, $J = 8.6$ Hz, 1 H), 7.23 (d, $J = 2.4$ Hz, 1 H), 6.75 (br s, 1 H), 6.60 (dd, $J = 5.7, 2.4$ Hz, 1 H), 4.19 (m, 1 H), 3.85 (s, 3 H), 3.38 (m, 2 H), 3.30 (s, 3 H), 2.34 (s, 3 H), 1.15 (d, $J = 6.7$ Hz, 3 H); MS (ESI) m/z : 448.2 ($M+H^+$).




Example 23: **Example C2** (0.10 g, 0.24 mmol) was dissolved in DCM (5 mL) and then mCPBA (60 mg, 0.24 mmol) was added portion wise. The mixture was stirred at RT mfor 2 hours. (R)-2-(methoxymethyl)pyrrolidine (0.28 g, 2.38 mmol) was added and then the mixture was stirred at RT overnight. The mixture was quenched with NaHCO₃ solution and the solution was extracted with DCM (2x). The organic was dried over Na₂SO₄, filtered and concentrated to obtain the crude. The material was purified via silica gel chromatography (MeOH/DCM) to obtain (R)-4-methoxy-2-(2-(methoxymethyl)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidine (96 mg, 83% yield). MS (ESI) *m/z*: 488.3 (M+H⁺).

[0219] (R)-4-methoxy-2-(2-(methoxymethyl)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidine (96 mg, 0.20 mmol) was dissolved in AcOH (3 mL) and then 48% hydrobromic acid (0.1 mL) was added. The mixture was heated at 90 °C FOR 3.5 hours. The mixture was concentrated and the residue was treated with NaHCO₃ solution. The solution was extracted with EtOAc (3x) and the organic was washed with NaHCO₃, dried over Na₂SO₄, filtered and concentrated to obtain the crude. The material was treated with ether and sonicated. The solid was filtered, washed with ether and dried under vacuum to obtain (R)-2-(2-(methoxymethyl)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (58 mg, 60.1% yield). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.15 (br s, 1 H), 8.73 (s, 1 H), 8.36 (d, *J* = 5.7 Hz, 1 H), 8.28 (br s, 1 H), 8.26 (s, 1 H), 7.97 (s, 1 H), 7.53 (m, 1 H), 7.23 (d, *J* = 2.4 Hz, 1 H), 6.62 (m, 1 H), 4.34 (m, 1 H), 3.85 (s, 3 H), 3.52-3.40 (m, 4 H), 3.28 (s, 3 H), 2.35 (s, 3 H), 1.95 (br d, *J* = 27.5 Hz, 4 H); MS (ESI) *m/z*: 474.3 (M+H⁺).




Example 24: **Example C2** (0.10 g, 0.24 mmol) was dissolved in DCM (5 mL) and then mCPBA (60 g, 0.24 mmol) was added. The mixture was stirred at RT for 2.5 hours. (3S)-(-)-3-(dimethylamino)pyrrolidine (0.27 g, 2.37 mmol) was added and then the mixture was stirred at RT overnight. The mixture was quenched with NaHCO₃ and extracted with DCM (2x). The organic was dried over Na₂SO₄, filtered and concentrated to obtain the crude. The material was purified via silica gel chromatography (MeOH/DCM) to obtain (S)-1-(4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-yl)-N,N-dimethylpyrrolidin-3-amine (100 mg, 86% yield). MS (ESI) *m/z*: 487.3 (M+H⁺).

[0220] (S)-1-(4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-yl)-N,N-dimethylpyrrolidin-3-amine (0.10 g, 0.21 mmol) was dissolved in AcOH (3 mL) and then 48% hydrobromic acid (0.1 mL) was added. The mixture was heated at 90 °C for 3.5 hours. The mixture was concentrated and the residue was treated with NaHCO₃ solution. The solution was extracted with EtOAc (3x) and the organic was washed with NaHCO₃, dried over Na₂SO₄, filtered and concentrated to obtain the crude. The crude was treated with hot MeCN and kept at RT. The solid was filtered, washed with MeCN, and dried under vacuum to obtain (S)-2-(3-(dimethylamino)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (62 mg, 62.8% yield). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.73 (s, 1 H), 8.36 (d, *J* = 5.7 Hz, 1 H), 8.29 (m, 1 H), 8.26 (s, 1 H), 7.97 (s, 1 H), 7.53 (d, *J* = 8.6 Hz, 1 H), 7.23 (d, *J* = 2.4 Hz, 1 H), 6.62 (dd, *J* = 5.7, 2.4 Hz, 1 H), 3.85 (s, 3 H), 3.74 (m, 2 H), 3.44 (m, 1 H), 3.31 (s, 3 H), 3.22 (m, 1 H), 2.75 (m, 1 H), 2.35 (s, 3 H), 2.18 (s, 6 H), 2.11 (m, 1 H), 1.77 (m, 1 H) one proton is missing; MS (ESI) *m/z*: 473.3 (M+H⁺).




Example 25: To a microwave vessel, **Example C3** (0.11 g, 0.26 mmol) was added and then 2.0M ethylamine in THF (10 mL, 20.00 mmol) was added. The mixture was heated at 100 °C for 2 days. The mixture was concentrated to obtain the crude. The crude was purified via silica gel chromatography (MeOH/DCM) to obtain 2-(ethylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (90 mg, 82% yield). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.69 (s, 1 H), 8.39 (d, *J* = 5.9 Hz, 1 H), 8.29

(m, 2 H), 8.01 (s, 1 H), 7.56 (m, 2 H), 7.30 (br s, 1 H), 6.68 (br s, 1 H), 3.86 (s, 3 H), 3.45 (m, 2 H), 3.36 (s, 4 H), 2.36 (s, 3 H), 1.18 (t, $J = 7.1$ Hz, 3 H); MS (ESI) m/z : 418.2 ($M+H^+$).




Example 26: To a microwave vessel, **Example C3** (0.11 g, 0.26 mmol) was added and then 2-methoxyethanamine (3 mL, 34.5 mmol) was added. The mixture was heated at 100 °C for 2 days. The mixture was concentrated to obtain the crude. The crude was purified via silica gel chromatography (MeOH/DCM) to obtain 2-((2-methoxyethyl)amino)-3-methyl-5-((6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (98 mg, 84% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 8.68 (s, 1 H), 8.37 (d, $J = 5.8$ Hz, 1 H), 8.28 (m, 2 H), 7.99 (s, 1 H), 7.57 (t, $J = 5.6$ Hz, 1 H), 7.54 (d, $J = 8.6$ Hz, 1 H), 7.27 (s, 1 H), 6.64 (m, 1 H), 3.85 (s, 3 H), 3.56-3.54 (m, 4 H), 3.37 (s, 3 H), 3.28 (s, 3 H), 2.35 (s, 3 H); MS (ESI) m/z : 448.2 ($M+H^+$).




Example 27: A solution of **Example C2** (0.200 g, 0.476 mmol) in DCM (5 mL) was treated with mCPBA (0.141 g, 0.571 mmol), stirred at RT for 3 h, treated with 4-aminotetrahydropyran hydrochloride (0.524 g, 3.81 mmol) and TEA (0.530 mL, 3.81 mmol) and stirred at RT overnight. Additional 4-aminotetrahydropyran hydrochloride (0.524 g, 3.81 mmol) and TEA (0.530 mL, 3.81 mmol) were added and the mixture stirred at RT for an additional 24 h. The mixture was concentrated to dryness, transferred to a sealed vessel with DMF (10 mL), treated with additional 4-aminotetrahydropyran hydrochloride (0.524 g, 3.81 mmol) and TEA (0.530 mL, 3.81 mmol) and heated at 60°C overnight. The mixture was cooled to RT, the solids removed via filtration and washed with DCM. The filtrate was treated with satd. NaHCO_3 , extracted with DCM (3x) and the combined organics were washed with 5% LiCl (3x), then brine, dried over Na_2SO_4 , concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford 4-methoxy-5-((6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-amine (125 mg, 56%). MS (ESI) m/z : 474.2 ($M+H^+$).

[0221] A solution of 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-amine (0.125 g, 0.264 mmol) in DCE (3 mL) was treated with TMS-I (1.078 mL, 7.92 mmol), heated at 60°C for 5 h, then cooled to RT and stirred overnight. The mixture was treated with 10% Na₂S₂O₃ and 1:1 THF/EtOAc, stirred for 0.5 h, the layers separated, the aqueous layer extracted with EtOAc (1x) and the combined organics were washed with brine, dried over MgSO₄ and concentrated to dryness. The material was treated with MeCN, heated to near-reflux and allowed to stand at RT over the weekend. The solid was removed via filtration, the filtrate concentrated to dryness and purified via silica gel chromatography (MeOH/EtOAc). The resulting material was treated with 10% MeOH/DCM, filtered to remove solids and concentrated to dryness to afford 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4(3H)-one (7.7 mg, 6%). ¹H NMR (400 MHz, DMSO-*d*₆): δ10.96 (br s, 1 H), 8.67 (s, 1 H), 8.35 (d, *J* = 5.7 Hz, 1 H), 8.29-8.24 (m, 2 H), 7.96 (s, 1 H), 7.51 (d, *J* = 8.6 Hz, 1 H), 7.22 (d, *J* = 2.4 Hz, 1 H), 7.00 (br s, 1 H), 6.60 (dd, *J* = 5.7, 2.4 Hz, 1 H), 3.98 (m, 1 H), 3.87-3.80 (m, 5 H), 3.39 (m, 2 H), 2.34 (s, 3 H), 1.85 (m, 2 H), 1.47 (m, 2 H); MS (ESI) *m/z*: 460.2 (M+H⁺).



Example 28: A solution of **Example C2** (0.100 g, 0.238 mmol) in DCM (5 mL) was treated with mCPBA (0.059 g, 0.238 mmol), stirred at RT for 2 h, treated with t-butylamine (0.4 mL, 3.81 mmol) and stirred at RT overnight. Additional t-butylamine (0.4 mL, 3.81 mmol) was added and the mixture stirred at RT for an additional 24 h. The mixture was concentrated to dryness, transferred to a sealed vessel with DMF (5 mL), treated with additional t-butylamine (0.4 mL, 3.81 mmol) and heated at 60°C overnight. The mixture was cooled to RT, the solids removed via filtration and washed with DCM. The filtrate was treated with satd. NaHCO₃, extracted with DCM (3x) and the combined organics were washed with 5% LiCl (3x), then brine, dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford N-(tert-butyl)-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (69 mg, 65%). MS (ESI) *m/z*: 446.3 (M+H⁺).

[0222] A solution of N-(tert-butyl)-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-2-amine (0.069 g, 0.155 mmol) in acetic acid (1.5 mL) was treated with HBr (48% aq., 0.071 mL, 0.623 mmol) and heated at 90°C for 4 h. The mixture was removed from heat, treated with ice and EtOAc, neutralized with satd. NaHCO₃, extracted with 1:1 EtOAc/THF (3x) and the combined organics were washed with brine, dried over MgSO₄ and concentrated to dryness. The resulting material was treated with MeCN, heated to near-reflux and allowed to stand at RT overnight. The solid was removed via filtration and the filtrate was concentrated to dryness and purified twice via silica gel chromatography (MeOH/DCM, then MeOH/EtOAc) to afford 2-(tert-butylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (11 mg, 15%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.59 (s, 1 H), 8.67 (s, 1 H), 8.37 (d, J = 5.6 Hz, 1 H), 8.27-8.22 (m, 2 H), 7.97 (s, 1 H), 7.52 (d, J = 8.9 Hz, 1 H), 7.23 (d, J = 2.6 Hz, 1 H), 6.60 (dd, J = 6.1, 2.6 Hz, 1 H), 6.52 (s, 1 H), 3.84 (s, 3 H), 2.34 (s, 3 H), 1.41 (s, 9 H); MS (ESI) *m/z*: 432.2 (M+H⁺).




Example 29: A solution of 2,2,2-trimethylacetamide (1.0 g, 9.89 mmol) in THF (100 mL) was treated slowly with LiAlH₄ (2.0M in THF, 14.83 mL, 29.7 mmol) and stirred at RT under Ar overnight. The mixture was slowly quenched with water (1.125 mL), 20% KOH (1.125 mL) and water (2.25 mL), stirred vigorously for 10 min, treated with Na₂SO₄, the solids removed via filtration through celite and the filter pad washed with THF. The filtrate was treated with 1M HCl in MeOH (15 mL) and concentrated to dryness to afford 2,2-dimethylpropan-1-amine hydrochloride (413 mg, 34%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.88 (br s, 2 H), 2.57 (s, 2 H), 0.93 (s, 9 H).

[0223] A solution of **Example C2** (0.100 g, 0.238 mmol) in DCM (5 mL) was treated with mCPBA (0.059 g, 0.238 mmol), stirred at RT for 2 h, treated with 2,2-dimethylpropan-1-amine hydrochloride (0.410 g, 3.32 mmol) and TEA (0.464 mL, 3.33 mmol) and stirred at RT for 5 days. The mixture was treated with satd. NaHCO₃, extracted with DCM (3x) and the combined organics were dried over Na₂SO₄, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford 4-methoxy-5-(6-methyl-5-((2-(1-methyl-

1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-N-neopentylpyrimidin-2-amine (81 mg, 74%). MS (ESI) m/z : 460.3 ($M+H^+$).

[0224] A solution of 4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-N-neopentylpyrimidin-2-amine (0.081 g, 0.176 mmol) in acetic acid (2 mL) was treated with HBr (48% aq, 0.080 mL, 0.705 mmol), heated at 80°C for 6 h, then cooled to RT overnight. The mixture was treated with ice and EtOAc, neutralized with satd. NaHCO_3 , extracted with EtOAc (3x) and the combined organics were washed with brine, dried over MgSO_4 and concentrated to dryness. The material was suspended in MeCN, heated to near-reflux and allowed to stand at RT for 3 h. The resulting solid was collected via filtration to afford 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(neopentylamino)pyrimidin-4(3H)-one (44 mg, 56%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.84 (s, 1 H), 8.68 (s, 1 H), 8.35 (d, $J = 6.6$ Hz, 1 H), 8.28-8.23 (m, 2 H), 7.96 (s, 1 H), 7.52 (d, $J = 8.6$ Hz, 1 H), 7.22 (d, $J = 3.0$ Hz, 1 H), 6.73 (br s, 1 H), 6.60 (dd, $J = 5.1, 2.3$ Hz, 1 H), 3.86 (s, 3 H), 3.22 (d, $J = 6.2$ Hz, 2 H), 2.34 (s, 3 H), 0.91 (s, 9 H); MS (ESI) m/z : 446.2 ($M+H^+$).



Example 30: **Example C2** (0.10 g, 0.24 mmol) was dissolved in DCM (5 mL) and then mCPBA (60 mg, 0.24 mmol) was added portion wise. The mixture was stirred at RT for 5 days (the reaction was very slow). The mixture was transferred to microwave vessel and heated at 40 °C for 2 days. The mixture was quenched with NaHCO_3 and the solution was extracted with DCM (2x). The organic was dried over Na_2SO_4 , filtered and concentrated to obtain the crude. The material was purified via silica gel chromatography (MeOH/DCM) to obtain 2-(3,3-difluoropyrrolidin-1-yl)-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidine (80 mg, 70% yield). MS (ESI) m/z : 480.2 ($M+H^+$).

[0225] A solution of 2-(3,3-difluoropyrrolidin-1-yl)-4-methoxy-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidine (0.080 g, 0.167 mmol) in AcOH (3 mL) was treated with 48% hydrobromic acid (0.1 mL). The mixture was heated at 90 °C for 3 hours. The mixture was concentrated and the residue was treated with NaHCO_3 and EtOAc. The mixture was stirred at RT. The solid was filtered and washed with water,

EtOAc, and dried under vacuum to obtain 2-(3,3-difluoropyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (42 mg, 52.3% yield). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.76 (br s, 1 H), 8.36 (d, J = 5.7 Hz, 1 H), 8.28 (br s, 1 H), 8.27 (s, 1 H), 7.97 (s, 1 H), 7.58 (br s, 1 H), 7.24 (d, J = 2.4 Hz, 1 H), 6.64 (s, 1 H), 3.96 (m, 2 H), 3.85 (s, 3 H), 3.76 (m, 2 H), 2.54 (m, 2 H), 2.37 (s, 3 H), one proton is missing; MS (ESI) *m/z*: 466.2 (M+H⁺).

[0226] The following assays demonstrate that certain compounds of Formula I inhibit kinase activity of c-FMS kinase, c-KIT kinase, or PDGFRβ kinase in enzymatic assays and also inhibit the activity of c-FMS kinase in M-NFS-60 and THP-1 cell lines. In vivo evaluations of certain compounds of Formula I also demonstrate inhibition of c-FMS in a pharmacodynamic model or also exhibit efficacy in a peritibial implant model, a U-251 or GL-261 glioma model, or in a MDA-MB-231 breast cancer xenograft model.

uFMS kinase (Seq. ID No. 1) Assay

[0227] Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler *et al.* Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340nm) was continuously monitored spectrophotometrically. The reaction mixture (100 μL) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl₂ (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 μM) in 90 mM Tris buffer containing 0.2 % octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30 °C on Synergy 2 plate reader. The reaction rate was calculated using the 3 to 4 h time frame. Percent inhibition was obtained by comparison of reaction rate with that of a control (i.e. in the absence of test compound). IC₅₀ values were calculated from a series of percent inhibition values determined at a range of inhibitor concentrations using software routines as implemented in the GraphPad Prism software package.

uFMS Kinase sequence (Y538-end) used for screening (Seq. ID No. 1)

YKYKQKPKYQ	VRWKHIESYE	GNSYTFIDPT	QLPYNEKWEF
	PRNNLQFGKT	LGAGAFGKVV	EATAFGLGKE
	DAVLKVAVKM	LKSTAHADK	EALMSELKIM SHLGQHENV

	NLLGACTHGG	PVLVITEYCC	YGDLLNFLRR
	KAEAMLGPSL	SPGQDPEGGV	DYKNIHLEKK
	YVRRDSGFSS	QGVDTYVEMR	PVSTSSNDSF SEQDLDKEDG
	RPLELRDLLH	FSSQVAQGMA	FLASKNCIHR
	DVAARNVLLT	NGHVAKIGDF	GLARDIMNDS
	NYIVKGNARL	PVKWMAPESE	FDCVYTVQSD
VWSYGILLWE	IFSLGLNPYP	GILVNSKFYK	LVKDGYYQMAQ
	PAFAPKNIYS	IMQACWALEP	THRPTFQQIC
	SFLQEQAQED	RRERDYTEMLP	SSSRSGGSGS SSSELEEES
	SEHLTCCEQG	DIAQPLLQPN	NYQFC

uKit kinase (Seq. ID No. 2) assay

[0228] Activity of unphosphorylated c-KIT kinase (uKIT, Seq. ID no. 2) was determined by following the production of ADP from the KIT kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler *et al.* Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340nm) was continuously monitored spectrophotometrically. The reaction mixture (100 µl) contained unphosphorylated KIT (12 nM), polyE4Y (1 mg/mL), MgCl₂ (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), and NADH (0.28 mM) and ATP (2000 µM) in 90 mM Tris buffer containing 0.2 % octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30 °C on Synergy 2 plate reader (BioTech). Reaction rates around 3 to 4 h time frame were used to calculate % inhibitions, from which IC₅₀ values were generated.

uKit with N-terminal GST fusion used for screening (Seq ID No. 2)

LGYWKIKGLV	QPTRLLLEYL	EEKYEEHLYE	RDEGDKWRNK
	KFELGLEFPN	LPYYIDGDVK	LTQSMAIRY
	IADKHNMLGG	CPKERAIEISM	LEGAVDIRYG VSRIAYSKDF
	ETLKVDFLSK	LPEMLKMFED	RLCHKTYLNG
	DHVTHPDFML	YDALDVVLYM	DPMCLDAFPK
	LVCFFKRIEA	IPQIDKYLKS	SKYIWPLQGW QATFGGGDHP
	PKSDLVPRHN	QTSLYKKAGS	AAAVLEENLY
	FQGTYYKYLQK	PMYEVQWKVV	EEINGNNYVY

	IDPTQLPYDH	KWEFPRNRLS	FGKTLGAGAF	GKVVEATAYG
	LIKSDAAMTV	AVKMLKPSAH	LTEREALMSE	
	LKVLSYLGNH	MNIVNLLGAC	TIGGPTLVIT	
	EYCCYGDLLN	FLRRKRDSFI	CSKQEDHAEA	ALYKNLLHSK
	ESSCSDSTNE	YMDMKPGVSY	VVPTKADKRR	SVRIGSYIER
DVTPAIMEDD	ELALDLEDLL	SFSYQVAKGM	AFLASKNCIH	
	RDLAARNILL	THGRITKICD	FGLARDIKND	
	SNYVVKGNAR	LPVKWMAPE	IFNCVYTFESD	VWSYGIFLWE
	LFSLGSSPYP	GMPVDSKFYK	MIKEGFRMLS	
	PEHAPAEMYD	IMKTCWDADP	LKRPTFKQIV	QLIEKQISES
	TNHIYSNLAN	CSPNRQKPVV		DHSVRINSVG
	STASSSQPLL	VHDDV		

Unphosphorylated PDGFR β (uPDGFR β) kinase (Seq. ID No. 3) assay

[0229] Activity of unphosphorylated PDGFR β kinase (uPDGFR β , Seq. ID No. 3) was determined by following the production of ADP from the kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler *et al.* Science (2000) 289: 1938-1942).. In this assay, the oxidation of NADH (thus the decrease at A340nm) was continuously monitored spectrophotometrically. The reaction mixture (100 μ L) contained PDGFR β (DeCode, 15.7 nM), polyE4Y (2.5 mg/mL), MgCl₂ (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM) and NADH (0.28 mM) and ATP (500 μ M) in a 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, at pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 h at 30 °C on a Polarstar Optima or Synergy 2 plate reader. The reaction rate was calculated using the 1.5 to 2.5 h time frame. Percent inhibition was obtained by comparison of reaction rate with that of a control (i.e. with no test compound). IC₅₀ values were calculated from a series of percent inhibition values determined at a range of inhibitor concentrations using software routines as implemented in the GraphPad Prism software package.

uPDGFR β Kinase Sequence (residues 557-1106) used for screening (Seq ID No. 3)

QKKP RYEIRW KVIE SVSSDG HEYI YVDPMQ LPYDSTWELP
 RDQLVLGRTL GSGAFGQVVE ATAHGLSHSQ ATMKVAVKML

KSTARSSSEKQ ALMSELKIMS HLGPLNLNVN LLGACTKGGP
 IYIITEYCRY GDLVDYLHRN KHTFLQHHSD KRRPPSAELY
 SNALPVGLPL PSHVSLTGE SDGGYMDMSK DESVDYVPML
 DMKGDVKYAD IESSNYMAPY DNYVPSAPER TCRAT LINES
 PVLSYMDLVG FSYQVANGME FLASKNCVHR DLAARNVLIC
 EGKLVKICDF GLARDIMRDS NYISKGSTFL PLKWMAPESI
 FNSLYTTLSL VWSFGILLWE IFTLGGTPYP ELPMNEQFYN
 AIKRGYRMAQ PAHASDEIYE IMQKCWEEKF EIRPPFSQLV
 LLLERLLGEG YKKKYQQVDE EFLRSDHPAI LRSQARLPGF
 HGLRSPLDTS SVLYTAVQPN EGDNDYIPL PDPKPEVADE
 GPLEGSPSLA SSTLNEVNTS STISCDSPLP PQDEPEPEPQ
 LELQVEPEPE LEQLPDSGCP APRAEAEDSF

L

[0230] Using the enzymatic protocols described above, compounds of Formula I were shown to be inhibitors in assays measuring the kinase activity of uFMS kinase, uKIT kinase, or uPDGFR β kinase, as indicated below in Table 1.

Table 1. Activity of Compounds of Formula Ia in Enzymatic Assays of uFMS kinase, uKIT kinase, or uPDGFR β kinase.

Example	uFMS	uKIT	uPDGFR β
1	+++	+	+
2	+++	+	+
3	++++	++	+
4	++	+	+
5	++	+	+
6	+++	++	+
7	++	++	+
8	+++	++	+
9	+++	+	+
10	++++	++	+
11	++	+	+
12	++	+	+
13	+++	+	+
14	++++	+	+
15	++++	++	++
16	++++	+	++
17	++++	+	+
18	++++	+++	+++

Example	uFMS	uKIT	uPDGFR β
19	+++	++	++
20	+++	++	++
21	+++	+	+
22	+++	+	+
23	+++	+	+
24	++	+	+
25	+++	++	+
26	+++	+	+
27	+++	+	+
28	++++	+++	+++
29	++++	+++	++
30	+++	+	+

NT: Not Tested; +: $IC_{50} > 1 \text{ uM}$; ++: $0.1 \text{ uM} < IC_{50} \leq 1 \text{ uM}$; +++: $0.01 \text{ uM} < IC_{50} \leq 0.1 \text{ uM}$; ++++: $IC_{50} \leq 0.01 \text{ uM}$

M-NFS-60 Cell Culture

[0231] M-NFS-60 cells (catalog #CRL-1838) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Briefly, cells were grown in suspension in RPMI 1640 medium supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA), 0.05 mM 2-mercaptoethanol, and 20 ng/mL mouse recombinant macrophage colony stimulating factor (M-CSF) at 37 °C, 5%CO₂, and 95% humidity. Cells were allowed to expand until reaching saturation at which point they were subcultured or harvested for assay use.

M-NFS-60 Cell Proliferation Assay

[0232] A serial dilution of test compound was dispensed into a 384-well black clear bottom plate (Corning, Corning, NY). Two thousand five hundred cells were added per well in 50 μ L complete growth medium. Plates were incubated for 67 h at 37 °C, 5%CO₂, and 95% humidity. At the end of the incubation period 10 μ L of a 440 μ M solution of resazurin (Sigma, St. Louis, MO) in PBS was added to each well and incubated for an additional 5 h at 37 °C, 5% CO₂, and 95% humidity. Plates were read on a Synergy2 reader (Biotek, Winooski, VT) using an excitation of 540 nM and an emission of 600 nM. IC_{50} values were calculated from a series of percent inhibition values determined at a range of inhibitor concentrations using software routines as implemented in the GraphPad Prism software package.

THP-1 Cell Culture

[0233] THP-1 cells (catalog #TIB-202) were obtained from the ATCC. Briefly, cells were grown in RPMI 1640 supplemented with 10% characterized fetal bovine serum, 1% sodium pyruvate, 1% Penicillin-Streptomycin-Glutamine (PSG) and 55uM 2-mercaptoethanol (Invitrogen, Carlsbad, CA) at 37 degrees Celsius, 5% CO₂, 95% humidity. Cells were allowed to expand until reaching 70-95% confluency at which point they were subcultured or harvested for assay use.

Phospho-FMS ELISA Assay

[0234] A serial dilution of test compound was diluted 1:100 in assay medium (RPMI 1640 supplemented with 10% characterized fetal bovine serum) in a 96 well black clear bottom plate (Corning, Corning, NY). In a separate 96 well black clear bottom plate, one hundred and fifty thousand THP-1 cells were added per well in 100 μ L in assay medium. Fifty microliters of diluted compound was then added to the cells. Plates were incubated for 4 hours at 37 degrees Celsius, 5% CO₂, 95% humidity. At the end of the incubation period, cells were stimulated with 50 μ L of a 100 nM solution of recombinant human M-CSF (catalog #216-MC, R & D Systems, Minneapolis, MN) in assay medium and the plate was incubated for 5 minutes at 37 degrees Celsius, 5% CO₂, 95% humidity. Lysates were prepared and used to perform the phospho-FMS ELISA as described by the manufacturer (catalog #DYC3268, R & D Systems, Minneapolis, MN). GraphPad Prism was used to calculate IC₅₀ values obtained from data generated from the ELISA assay.

Osteoclast Tartrate-Resistant Acid Phosphatase Assay

[0235] A serial dilution of test compound was dispensed into a 384-well black clear bottom plate (Nalge Nunc International, Rochester, NY). Compound was diluted by the addition of DMEM media supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA). Diluted compound was transferred to a 384-well black clear bottom plate. Two-thousand five hundred osteoclast precursors (Lonza, Walkersville, MD) were added per well in growth media containing Receptor Activator of Nuclear Factor Kappa-beta ligand (RANKL) and M-CSF (R&D Systems, Minneapolis, MN). Plates were incubated for 7-14 days at 37 degrees Celsius, 5% CO₂, and 95% humidity to allow differentiation of osteoclast precursors. At the end of the incubation period, 10 μ L of supernatant from each well was transferred to a clear 384-well plate. Tartrate-resistant acid phosphatase activity in the supernatant samples was determined using an acid phosphatase

assay kit (Sigma, St. Louis, MO). Absorbance was measured at 550 nm using a plate reader. Data was analyzed using Prism software (Graphpad, San Diego, CA) to calculate IC₅₀ values.

[0236] The compounds of formula I were demonstrated to be functional inhibitors in one or more of the cellular assays described above, as indicated in Table 2.

Table 2. Inhibitory effects of compounds of formula I versus M-NFS-60, THP-1 and Osteoclast Cells

Example	M-NFS-60 cell proliferation	Osteoclast assay	pFMS inhibition in THP-1 cells
1	+++	+++	+++
2	++	+++	NT
3	++++	+++	++++
4	+	++	NT
5	+	++	NT
6	++	+++	NT
7	+	++	NT
8	+++	++	NT
9	+++	+++	+++
10	++++	++++	+++
11	++	+++	NT
12	++	+++	NT
13	+++	+++	+++
14	+++	+++	+++
15	++++	++++	+++
16	++++	++++	+++
17	+++	++++	+++
18	++++	++++	++++
19	++	+++	NT
20	+++	++++	+++
21	+++	+++	+++
22	+++	++++	++
23	+++	+++	NT
24	++	++	NT
25	+++	+++	+++
26	+++	+++	+++
27	++	+++	++
28	+++	+++	+++
29	+++	+++	+++
30	++	+++	+++

NT: Not Tested; +: IC₅₀ > 1 uM; ++: 0.1 uM < IC₅₀ ≤ 1 uM; +++: 0.01 uM < IC₅₀ ≤ 0.1 uM; ++++: IC₅₀ ≤ 0.01 uM

Measurements of *in vivo* Activity

Analysis of cFOS mRNA production in a c-FMS mouse spleen pharmacodynamic model

[0237] To examine the *in vivo* modulation of FMS activity by compounds of formula I, spleen samples from female DBA/1 mice were collected and analyzed for M-CSF stimulated production of cFOS mRNA. Briefly, six to seven week old female Taconic DBA/1BO J Bom Tac mice were treated with a single oral dose (by gavage) of either vehicle or compound. Plasma and spleen samples were collected from four mice at each timepoint 2, 4, 6, 8, 12, 18, and 24 hours after dosing. Fifteen minutes prior to euthanasia, all mice were injected IV with 1 μ g (100 μ L fixed volume) of M-CSF. M-CSF, Recombinant Mouse Macrophage Colony Stimulating Factor (36.4 kDa homodimer, $\geq$ 98% purity) was obtained from Gibco. All procedures carried out in this experiment were conducted in compliance with all the laws, regulations and guidelines of the National Institutes of Health (NIH). cFOS mRNA levels in spleen extracts were determined using a quantitative reverse transcriptase PCR kit from Life Technologies. Plasma levels of FMS inhibitors were determined by mass spectrometer analysis. The degree of FMS inhibition was correlative to the amount of decrease observed in cFOS mRNA levels in the spleen samples of treated animals compared to vehicle.

[0238] In this model, Examples 3, 9 and 10 afforded $\geq$ 70% inhibition of cFOS mRNA levels out to 8 h post 30 mg/kg dose.

PC-3 peritibial implant model of cancer bone metastasis

[0239] To evaluate *in vivo* anti-cancer activity of compounds of formula I, the PC-3 M-luc peritibial injection model of bone invasiveness model was employed. Briefly, PC-3 M-luc cells were obtained from Xenogen Corporation (Caliper Life Sciences) and expanded using MEM media modified with L-Glutamine (Cell Gro® #10-045-CV) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin-glutamine, 1% non-essential amino acids, and 1% MEM vitamins in 5%CO₂ atmosphere at 37°C. Six to 7 week old male nude mice (CrI:NU-Foxn1nu) were obtained from Charles River Laboratories. Test mice were implanted peritibially on Day 0 with 1x10⁶ cells/mouse (0.1ml) using an insulin syringe with a fixed 28-gauge needle. The needle was inserted at the ankle between the tibia and fibula until the bevel of the needle reached approximately half way between the knee and ankle. Treatments began on Day 0. Animals were dosed by oral gavage twice daily for the study duration. All procedures carried out in this experiment were conducted in compliance with all the laws, regulations and guidelines of the National Institutes of Health (NIH). When the primary tumor reached approximately 800 mg in size, ex-vivo micro-CT was performed on

the tumor bearing fixed hind limb samples using a GE RS150 small animal micro-CT scanner using with the following settings:

X-ray tube voltage = 70kVp

X-ray tube current = 25 mA

Exposure time = 20ms

Number of frames = 500

Angle increment between frames = 0.4o

Number of averages per frame = 2

Acquisition method = Parker

[0240] Images were then reconstructed at high resolution (100 microns;isotropic). Isosurface volume renderings were used to delineate lesions in the hind limbs. A constant threshold was used to produce consistent representation of the isosurface between different anatomical sites and samples. Lesions in the right hind limb were scored with values of 0, 1, 2, 3, or 4 based on a qualitative assessment of lesion size as defined by:

0: Normal Bone

1: Minimal lesions. Some roughening of the isosurface. Small areas of apparent bone resorption.

2: Mild. More numerous lesions. Significant roughening of the isosurface. Full thickness lesions apparent.

3: Moderate. Full thickness lesions larger and more numerous.

4: Marked. Many, large, full thickness lesions. Significant distortion of remaining structure. Marked bone loss.

[0241] Example 10 was evaluated in this model at an oral dose of 30 mg/kg given twice daily for 39 days and demonstrated positive benefit with a lesion score of 2 compared to a lesion score of 4 in vehicle-treated animals.

U251 Intra-cerebro-ventricular implant in mice

[0242] To evaluate in vivo anti-cancer activity compounds of formula I in combination with fractionated, localized head radiation, an orthotopic U251-luc (Luc) human glioma carcinoma model in female outbred nu/nu mice is employed. Briefly, U251 cells are obtained from the ATCC and altered to be luciferase expressing. They are grown in RPMI 1640 Media supplemented with 10% FBS and 1% PSG. The growth environment is maintained in an incubator with a 5% CO₂ atmosphere at 37°C. Female Harlan Nude mice (Hsd:AthymicNude-Fox1nu) 8-9 weeks old are used in this study. Test animals are

implanted intracranially with U251-luc (LucmCherry) cells. Briefly, animals are injected subcutaneously with 5mg/kg carprofen and anesthetized using 2% isoflurane in air. The animals are then secured in a stereotaxic frame (ASL instruments, Inc.) and a hole drilled 2mm right lateral, 1mm anterior to the coronal suture. The cell suspension (stored on wet ice) is mixed thoroughly and drawn up into a 50 μ l syringe. The syringe needle is centered over the burr hole and lowered 3mm into the brain and retracted 1mm to form a “reservoir” for the deposition of the cell suspension. 10 μ l of the cell suspension (1×10^6 cells/mouse) is then injected slowly into the brain tissue. Tumor progression is tracked with *in vivo* bioluminescence imaging performed using an IVIS 50 optical imaging system (Xenogen, Alameda, CA). Bioluminescence images are acquired at periodic intervals for tumor burden estimation. All procedures carried out in this experiment are conducted in compliance with all the laws, regulations and guidelines of the National Institutes of Health (NIH). Treatment begins when the mean brain bioluminescence signal for all groups in the experiment is $\sim 1.3 \times 10^9$ photons/sec (typically 9 days post-implant). All mice receive 2Gy of radiation each day for five consecutive days from a RadSource RS-2000 irradiator. Additionally, mice receive test compound dosed by oral gavage or optionally with co-administered bevacizumab by tail vein injection. Bioluminescence images are acquired generally on days 8, 10, 14, 17, 21, 22, 24, 28 and 35 post-implant for tumor burden estimation. For each measurement, each mouse is injected subcutaneously with 150mg/kg D-Luciferin (Promega) and imaged 10 minutes after the injection. Images are analyzed using Living Image (Xenogen, Alameda, CA) software. The BLI signal in the brain is calculated with a fixed area ROI to estimate the tumor burden. Average BLI signal for each group is compared to vehicle control to determine therapeutic benefit. Twenty-eight days after the first radiation treatment mice are euthanized, via over-exposure to carbon dioxide, for blood and brain collection. Whole blood is collected via terminal cardiac puncture and placed into EDTA Microtainer® tubes. Brains are excised and placed into 10% neutral buffered formalin.

GL261 intracranial implant model

[0243] To evaluate the *in vivo* anti-cancer activity of compounds of formula I, an intracranial implant of GL261-luc2 murine glioma is employed. Briefly GL261-luc2 cells are obtained from Caliper Life Sciences, Inc and expanded in Dulbecco's Modified Eagle Media (DMEM) which is supplemented with 10% FBS and 1% PSG. The growth environment is maintained in an incubator with a 5% CO₂ atmosphere at 37°C. Following expansion, cells are re-suspended using serum-free media to generate a concentration of 1×10^8 cells/mL. Six

to seven week old female C57BL/6J-*Tyrc-2J/J* from Jackson Labs are implanted intracranially on Day 0 with GL261-luc2 cells. For aseptic surgical implantation, animals are injected subcutaneously with 5mg/kg carprofen, anesthetized using 2% isoflurane in air. The animals are then secured in a stereotaxic frame (ASL instruments, Inc.) and a hole is drilled 2mm right lateral, 1mm anterior to the coronal suture. The cell suspension (stored on wet ice) is mixed thoroughly and drawn up into a 50 μ L syringe. The syringe needle is centered over the burr hole and lowered 3mm into the brain and retracted 1mm to form a “reservoir” for the deposition of the cell suspension. 10 μ L of the cell suspension (1×10^6 cells/mouse) is then injected slowly into the brain tissue. Tumor progression is tracked with *in vivo* bioluminescence imaging performed using an IVIS 50 optical imaging system (Xenogen, Alameda, CA). Bioluminescence images are acquired at periodic intervals for tumor burden estimation. The quantity of emitted light from the tumor after systemic injection of D-Luciferin is expected to correlate with tumor size. Each mouse is injected intraperitoneally (IP) with 150mg/kg D-Luciferin and imaged in the prone position 10 minutes after the injection. Medium and small binning of the CCD chip is used, and the exposure time is adjusted (10 seconds to 1 minute) to obtain at least several hundred counts from the tumors and to avoid saturation of the CCD chip. Images are analyzed using Living Image (Xenogen, Alameda, CA) software. Each unique signal is circled manually and labeled by group and mouse number. Treatment begins by oral gavage of test compound when the mean brain bioluminescence signal for all groups in the experiment is 280×10^6 photons/sec. All procedures carried out in this experiment are conducted in compliance with all the laws, regulations and guidelines of the National Institutes of Health (NIH).

[0244] At the end of study all mice are euthanized via over-exposure to carbon dioxide for blood and brain collection. Whole blood is collected via terminal cardiac puncture and placed into EDTA Microtainer® tubes. Brains are excised and placed into 10% neutral buffered formalin.

MDA-MB-231 xenograft study

[0245] To evaluate the *in vivo* anti-cancer activity compounds of formula I, a MDA-MB-231-luc-D3H2LN human breast carcinoma xenograft is employed. Briefly, MDA-MB-231-luc-D3H2LN cells are obtained from Xenogen and expanded in Minimal Essential Media (MEM) with EBSS which is modified with 1% L-glutamine and supplemented with 10% FBS, 1% PSG, 1% non-essential amino acids, and 1% sodium pyruvate. The growth environment is maintained in an incubator with a 5% CO₂ atmosphere at 37°C. Cells are

harvested and re-suspended using 50% serum-free media and 50% Matrigel[®] to generate a stock concentration of 5×10^6 cells/mL.

[0246] Six to 7 week old female C.B-17/IcrHsd-PrkdcscidLystbg mice are injected with 200 μ L of cell suspension subcutaneously, just below the right axilla. All procedures carried out in this experiment are conducted in compliance with all the laws, regulations and guidelines of the National Institutes of Health (NIH). Treatment begins when the mean tumor burden is approximately 150 mg. All mice are dosed with test compound by oral gavage. Body weights and tumor measurements are recorded three times weekly. Tumor burden (mg) is estimated from caliper measurements by the formula for the volume of a prolate ellipsoid assuming unit density as: Tumor burden (mg) = $(L \times W^2)/2$, where L and W are the respective orthogonal tumor length and width measurements (mm). The primary endpoints to evaluate efficacy is %T/C. %T/C is defined as the median tumor mass of a Treated Group divided by the median tumor mass of the Control Group x 100. Ex vivo bioluminescence imaging is performed as animals exit the study, using an IVIS 50 optical imaging system (Xenogen, Alameda, CA). Animals are injected IP with 150mg/kg D-Luciferin (Promega) and euthanized 10 minutes following the injection. The primary tumor is removed and snap frozen for future analysis and the mouse opened and imaged in the supine position. Large binning of the CCD chip is used, and the exposure time is adjusted (1 to 2 minutes) to obtain at least several hundred counts from the tumors and to avoid saturation of the CCD chip. Images are analyzed using Living Image (Xenogen, Alameda, CA) software. Each unique signal is circled manually and labeled by group and mouse number. Total BLI signal is correlative to tumor size and compared to vehicle control to determine treatment benefit.

[0247] Certain 2-aminopyrimidin-6-ones have been reported to be inhibitors of VEGFR/KDR and/or c-MET kinases in WO2008/079291 and are illustrated in Figure 1, below. Evidence of kinase inhibition was only reported for certain inhibitors of WO2008/079291 versus cMET kinase, with K_i 's ranging from 6-87 nM (indicated in Figure 1). No information regarding inhibition of c-FMS kinase was disclosed in WO2008/079291. These compounds of WO2008/079291 differ from compounds of the instant invention by the presence of an arylamino "A" moiety in Formula I of the instant invention [wherein A is NR₂(R₃), R₂ is aryl and R₃ is H].

[0248] These compounds of WO2008/079291 are outside the scope of the instant invention. Nonetheless, the compounds of the instant invention have been screened against

both c-MET and KDR kinase. Unexpectedly, it has been found that the compounds of the instant invention afford high levels of selectivity for c-FMS kinase versus c-MET and KDR kinases. The most potent compound of Formula I in the c-MET assay exhibited an IC_{50} value of 3.4 micromolar, versus 0.0016 micromolar in the u-FMS assay, a selectivity of 2125-fold. The most potent compound of Formula I in the KDR assay exhibited an IC_{50} value of 1.4 micromolar, versus 0.0016 micromolar in the u-FMS assay, a selectivity of 875-fold. These data evidence that compounds of the present invention (A is non-aromatic moiety) potently inhibit c-FMS kinase but do not readily inhibit cMET and KDR kinase activity. These results could not be anticipated by the prior teachings of WO2008/079291.




Figure 1. cMET inhibitors of WO2008/079291.


Equivalents

[0249] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically in this disclosure. Such equivalents are intended to be encompassed in the scope of the following claims.

CLAIMS

What is claimed is:

1. A compound of **Formula I**,




Formula I

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein

A is taken from the group consisting of $-N(R_2)R_3$ and G;

G is selected from the group consisting of



and wherein the symbol (**) is the point of attachment to the pyrimidine ring;

each G moiety may be further substituted with one, two, or three R₄ moieties;

W is C₅-C₆heteroaryl, phenyl, $-NHC(O)R_6$, $-NHC(O)R_7$, $-NHC(O)N(R_8)R_9$ or $-C(O)N(R_8)R_9$, and wherein each C₅-C₆heteroaryl or phenyl is optionally substituted by one, two, or three R₅ moieties;

X₁ and X₂ are individually and independently hydrogen or C₁-C₆ alkyl;

R₁ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, or branched C₃-C₈ alkyl;

R₂ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, branched C₃-C₈ alkyl, C₃-C₈ cycloalkyl, fluoroC₁-C₆alkyl wherein the alkyl is fully or partially fluorinated, $-(CH_2)_m-OR_8$, or a 3-8 membered non-aromatic heterocycle, wherein each alkylene is optionally substituted with C₁-C₄ alkyl;


R₃ is hydrogen, C₁-C₆ alkyl, deuterio-C₁-C₆ alkyl wherein the alkyl chain is partially or completely deuterated, branched C₃-C₈ alkyl, C₃-C₈ cycloalkyl, fluoroC₁-C₆alkyl wherein the alkyl is fully or partially fluorinated or a 3-8 membered non-aromatic heterocycle;

each R4 is individually and independently hydrogen, halogen, C1-C6 alkyl, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, $-(CH_2)_m-R_7$, or cyano, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R5 is individually and independently hydrogen, C1-C6 alkyl, deuterio-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, halogen, cyano, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, $-(CH_2)_m-C(O)NR_8(R_9)$, $-(CH_2)_m-C(O)R_7$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl;

Each R6 is individually and independently hydrogen, C1-C6 alkyl, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m-CN$, $-(CH_2)_m-OR_8$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-R_7$, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R7 is independently and individually selected from the group consisting of



and wherein the symbol (##) is the point of attachment to respective W, R5 or R6 moieties containing a R7 moiety;

each R7 is optionally substituted with $-(R_{10})_p$;

each R8 and R9 is individually and independently hydrogen, C1-C6 alkyl, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, or branched C3-C8 alkyl;


each R10 is individually and independently C1-C6 alkyl, $-(CH_2)_m-CN$, $-(CH_2)_m-OR_3$, $-(CH_2)_m-NR_8(R_9)$, or $-(CH_2)_m-C(O)-R_6$, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl;

wherein each alkylene is optionally substituted with C1-C4 alkyl

each m is individually and independently 0, 1, 2, or 3; and


each p is 0, 1, 2, or 3.

2. The compound of claim 1 wherein the compound is a compound of **Formula Ia**,


**Formula Ia**

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.

3. The compound of claim 2 wherein R3 is hydrogen.
4. The compound of claim 3 wherein the compound is a compound of **Formula Ib**,


**Formula Ib**

5. The compound of claim 4 wherein one of X1 and X2 is C1-C6alkyl and the other is hydrogen.
6. The compound of claim 5, wherein R1 is hydrogen.
7. The compound of claim 5, wherein R1 is C1-C6alkyl.
8. The compound of claim 1 wherein the compound is a compound of **Formula Ic**,

**Formula Ic**

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.

9. The compound of claim 8 wherein the compound is a compound of **Formula Id**,

**Formula Id**

10. The compound of claim 9 wherein one of X1 and X2 is C1-C6alkyl and the other is hydrogen.
11. The compound of claim 10, wherein R1 is hydrogen.
12. The compound of claim 10, wherein R1 is C1-C6alkyl.
13. A compound selected from the group consisting of 2-(ethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(dimethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(6-methyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(6-methyl-5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-((2-methoxyethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(methylamino)pyrimidin-4(3H)-one, 2-(ethylamino)-5-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 4-((6-(2-(isopropylamino)-6-oxo-1,6-dihydropyrimidin-5-yl)pyridin-3-yl)oxy)-N-methylpicolinamide, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-morpholinopyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(piperidin-1-yl)pyrimidin-4(3H)-one, 2-(cyclopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(cyclopentylamino)-5-(6-methyl-5-((2-

(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 2-(cyclopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(isopropylamino)-5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, N-(4-((6-(2-(isopropylamino)-6-oxo-1,6-dihydropyrimidin-5-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)acetamide, 5-(4-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(pyrrolidin-1-yl)pyrimidin-4(3H)-one, 5-(5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-methylpyridin-2-yl)-2-(isopropylamino)pyrimidin-4(3H)-one, (R)-2-((1-methoxypropan-2-yl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, (R)-2-(2-(methoxymethyl)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, (S)-2-(3-(dimethylamino)pyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-(ethylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 2-((2-methoxyethyl)amino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4(3H)-one, 2-(tert-butylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, 5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-(neopentylamino)pyrimidin-4(3H)-one, and 2-(3,3-difluoropyrrolidin-1-yl)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.

14. A pharmaceutical composition, comprising a compound of claim 13 and a pharmaceutically acceptable carrier.
15. The compound 2-(ethylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.
16. A pharmaceutical composition, comprising the compound of claim 15 and a pharmaceutically acceptable carrier.

17. The composition of claim 16 further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.
18. The compound 2-(isopropylamino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.
19. A pharmaceutical composition, comprising the compound of claim 18 and a pharmaceutically acceptable carrier.
20. The composition of claim 19 further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.
21. The compound 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one.
22. A pharmaceutical composition, comprising the compound of claim 21 and a pharmaceutically acceptable carrier.
23. The composition of claim 22 further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.
24. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
25. The composition of claim 24 further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.
26. Use of of a compound of claim 1 in the manufacture of a medicament for the treatment of melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, or osteoporosis.

27. Use of a compound of claim 1 in the manufacture of a medicament for the treatment of glioblastomas, breast cancers, pancreatic cancers, or cancers that are metastatic to bone.
28. The use of any one of claims 26 or 27, wherein the compound is to be administered orally, parenterally, by inhalation, or subcutaneously.
29. A compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, non-small cell lung cancer, colonic cancers, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune

nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, or osteoporosis.

30. A compound of claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of glioblastomas, breast cancers, pancreatic cancers or cancers that are metastatic to bone.